## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2022-03-23_Virtual Town Hall 81_fixnames.md
last updated: 2025-01-05 Created QA Sections
link pdf: https://www.fda.gov/media/157366/download?attachment
link youtube: https://youtu.be/E3GehMsbvpY
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on COVID-19 Testing Guidance

QA Block 1-1
CLARIFIED QUESTION: What are the specific steps for developers to access and use Emory University and Children's Healthcare of Atlanta's Master File on pediatric self-swabbing?
CLARIFIED ANSWER: Developers should contact their FDA lead reviewer to access Emory University and Children's Healthcare of Atlanta's Master File on pediatric self-swabbing. The FDA plans to add related information to its FAQs online.
VERBATIM QUESTION: What are the specific steps for developers to access and use Emory University and Children's Healthcare of Atlanta's Master File on pediatric self-swabbing?
VERBATIM ANSWER: Emory University and Children's Healthcare of Atlanta have granted a right of reference to any developer looking to include pediatric cell swabbing for their COVID-19 tests that-- those developers can leverage the performance data and specimen collection protocols from the study on pediatric self-swabbing. And they've submitted this data to FDA in a Master File. So any developers that are interested in leveraging this information should reach out to their lead reviewer. And we will be putting information about this up on our website in the FAQs as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Master File on pediatric self-swabbing, COVID-19 diagnostics, Access for test developers
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: How should developers approach the FDA lead reviewers to leverage the pediatric swabbing study data?
CLARIFIED ANSWER: Developers interested in leveraging the pediatric swabbing study data should contact their FDA lead reviewer. The study data is available in a Master File and can be referenced for pediatric self-swabbing in COVID-19 tests.
VERBATIM QUESTION: How should developers approach the FDA lead reviewers to leverage the pediatric swabbing study data?
VERBATIM ANSWER: Emory University and Children's Healthcare of Atlanta have granted a right of reference to any developer looking to include pediatric cell swabbing for their COVID-19 tests that-- those developers can leverage the performance data and specimen collection protocols from the study on pediatric self-swabbing. And they've submitted this data to FDA in a Master File. So any developers that are interested in leveraging this information should reach out to their lead reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pediatric swabbing study, FDA lead reviewers, COVID-19 test development
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What details will be included in the website FAQs about pediatric self-swabbing?
CLARIFIED ANSWER: The FDA will include information in the FAQs about the right of reference for developers to use pediatric self-swabbing performance data and specimen collection protocols from the Emory University and Children's Healthcare of Atlanta study, submitted in a Master File.
VERBATIM QUESTION: What details will be included in the website FAQs about pediatric self-swabbing?
VERBATIM ANSWER: Emory University and Children's Healthcare of Atlanta have granted a right of reference to any developer looking to include pediatric cell swabbing for their COVID-19 tests that-- those developers can leverage the performance data and specimen collection protocols from the study on pediatric self-swabbing. And they've submitted this data to FDA in a Master File. So any developers that are interested in leveraging this information should reach out to their lead reviewer. And we will be putting information about this up on our website in the FAQs as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pediatric self-swabbing, FAQ updates, developer resources
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What additional precautions should manufacturers consider to prevent improper use of at-home COVID-19 tests?
CLARIFIED ANSWER: FDA emphasized that manufacturers should remind consumers to keep at-home COVID-19 tests out of reach of children and pets, and to carefully follow test instructions to avoid misuse.
VERBATIM QUESTION: What additional precautions should manufacturers consider to prevent improper use of at-home COVID-19 tests?
VERBATIM ANSWER: As noted in the safety communication, we have received some reports of individuals using them inappropriately, mistaking the vials of reagent for eye drops, or children getting a hold of them and drinking the solution. So obviously, these are not ideal situations, and we have issued the safety communication just to add some clarity there and to remind people to keep the tests out of reach of children and pets, and to follow the manufacturer's test instructions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: At-home COVID-19 test safety, Preventing misuse, Manufacturer precautions
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: What guidance does the FDA provide on the proper storage of at-home COVID-19 tests to minimize risks to children and pets?
CLARIFIED ANSWER: The FDA advises keeping at-home COVID-19 tests out of reach of children and pets, following the manufacturer's test instructions, to prevent misuse or accidental ingestion of reagents.
VERBATIM QUESTION: What guidance does the FDA provide on the proper storage of at-home COVID-19 tests to minimize risks to children and pets?
VERBATIM ANSWER: As noted in the safety communication, we have received some reports of individuals using them inappropriately, mistaking the vials of reagent for eye drops, or children getting a hold of them and drinking the solution. So obviously, these are not ideal situations, and we have issued the safety communication just to add some clarity there and to remind people to keep the tests out of reach of children and pets, and to follow the manufacturer's test instructions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Proper storage of COVID-19 tests, Safety precautions for children and pets, Manufacturer's use instructions
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How should developers address concerns about toxic chemicals in at-home tests when communicating with consumers?
CLARIFIED ANSWER: FDA advises developers to emphasize proper usage of at-home COVID tests by following instructions, keeping them away from children and pets, and addressing potential toxic chemical concerns through clear safety communications and FAQs.
VERBATIM QUESTION: How should developers address concerns about toxic chemicals in at-home tests when communicating with consumers?
VERBATIM ANSWER: We recently put up a safety communication regarding-- as well as a couple of FAQs regarding the use of at-home COVID-19 tests and the need to use them properly, according to the manufacturer's test instructions, in order for them to continue to be safe and to avoid potential harm. As noted in the safety communication, we have received some reports of individuals using them inappropriately, mistaking the vials of reagent for eye drops, or children getting a hold of them and drinking the solution. So obviously, these are not ideal situations, and we have issued the safety communication just to add some clarity there and to remind people to keep the tests out of reach of children and pets, and to follow the manufacturer's test instructions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Toxic chemical safety, At-home COVID tests, Consumer communication
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: Are there any specific updates developers should be aware of regarding the expiration dates of at-home COVID-19 tests?
CLARIFIED ANSWER: FDA has published an FAQ on their website regarding expiration dates for at-home COVID-19 tests.
VERBATIM QUESTION: Are there any specific updates developers should be aware of regarding the expiration dates of at-home COVID-19 tests?
VERBATIM ANSWER: And along with that safety communication, we put out an FAQ about the safety of at-home COVID tests and the potential toxic chemicals. And we also put up an FAQ about expiration dates for home COVID tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: At-home test expiration dates, FDA FAQs
REVIEW FLAG: False


#### 2. Conversion of EUAs to Full FDA Authorizations

QA Block 2-1
CLARIFIED QUESTION: What are the specific steps required to transition a COVID-19 test from an EUA to a full 510k authorization?
CLARIFIED ANSWER: Molecular tests can follow a 510k process for point-of-care use, while others may require the de novo pathway. Recommendations for submitting full authorization packages are consistent, and sponsors are encouraged to use the FDA's Pre-Sub and Q-Sub pathways for support during the transition process.
VERBATIM QUESTION: What are the specific steps required to transition a COVID-19 test from an EUA to a full 510k authorization?
VERBATIM ANSWER: All molecular test follow-ons will, for point of care laboratory use, can be handled through the 510k process. Where that's not available, then de novo pathway is the process. And for the first successful submitter, all subsequent submitters will then be authorized under the 510k pathway. ... The first one in for antigen will use molecular comparators, and the second one that's a 510k will also use molecular comparators. So we are able to provide recommendations, at least through the Pre-Sub and Q-Sub process for COVID test full authorization conversions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA authorization process, EUA to 510k transitions, Pre-Sub/Q-Sub process
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Are there additional validation requirements for the first de novo submission compared to follow-on 510k submissions?
CLARIFIED ANSWER: There are no additional validation requirements for the first de novo submission compared to follow-on 510k submissions; the testing and validation are essentially the same.
VERBATIM QUESTION: Are there additional validation requirements for the first de novo submission compared to follow-on 510k submissions?
VERBATIM ANSWER: But I did want to make it clear that there's really nothing different between the first de novo and the second 510k, for any of the areas as far as what our recommendations are for full authorization. The testing, the validation is essentially the same.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: de novo vs. 510k requirements, validation, FDA recommendations
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What role do molecular comparators play in transitioning antigen tests to full authorization?
CLARIFIED ANSWER: Molecular comparators are used for both the first de novo application and subsequent 510k applications when transitioning antigen tests to full authorization.
VERBATIM QUESTION: What role do molecular comparators play in transitioning antigen tests to full authorization?
VERBATIM ANSWER: So the first one in for antigen will use molecular comparators, and the second one that's a 510k will also use molecular comparators.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: molecular comparators, full authorization, antigen tests
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: When should developers begin considering the conversion from an EUA to a full authorization for their tests?
CLARIFIED ANSWER: The FDA recommends that developers begin considering the conversion from an EUA to full authorization during their EUA studies, as it is more efficient to continue studies for full authorization once EUA data is collected. It is not required, but now is an opportune time given the stage of the pandemic.
VERBATIM QUESTION: When should developers begin considering the conversion from an EUA to a full authorization for their tests?
VERBATIM ANSWER: I would say also that, especially those that are planning to do EUA studies now, whether it be antigen, molecular, or serology-- well into the third year of the pandemic, if you're doing that now, presumably you want to stay on the market for a long time. And therefore, I would recommend that you, while you're doing your EUA studies, consider continuing those studies after you get enough data to submit for an EUA and collect for the full authorization. It just seems relatively efficient for you to do that, rather than start something, stop it, and then have to restart later. So something to consider-- it's something that I would recommend, but it's certainly not a requirement. It just seems to make sense at this time in the pandemic on when we're encouraging all EUAs to go ahead and perform their conversion studies. Alright, and there's no time like the present to get that started.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA to full authorization, COVID-19 diagnostic tests, FDA study recommendations
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: What are the reasons for recommending developers to continue EUA studies into full authorization studies without interruption?
CLARIFIED ANSWER: FDA recommends continuing EUA studies into full authorization studies to maintain market presence efficiently, avoiding the need to stop and restart studies. This approach aligns with the current stage of the pandemic.
VERBATIM QUESTION: What are the reasons for recommending developers to continue EUA studies into full authorization studies without interruption?
VERBATIM ANSWER: I would say also that, especially those that are planning to do EUA studies now, whether it be antigen, molecular, or serology-- well into the third year of the pandemic, if you're doing that now, presumably you want to stay on the market for a long time. And therefore, I would recommend that you, while you're doing your EUA studies, consider continuing those studies after you get enough data to submit for an EUA and collect for the full authorization. It just seems relatively efficient for you to do that, rather than start something, stop it, and then have to restart later. So something to consider-- it's something that I would recommend, but it's certainly not a requirement. It just seems to make sense at this time in the pandemic on when we're encouraging all EUAs to go ahead and perform their conversion studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA studies, Full authorization, FDA recommendations
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: How might a potential resurgence in COVID-19 cases impact the data collection process for EUA or full authorization submissions?
CLARIFIED ANSWER: A resurgence in COVID-19 cases may result in an increased number of positive cases, which could facilitate data collection for EUA or full authorization studies.
VERBATIM QUESTION: How might a potential resurgence in COVID-19 cases impact the data collection process for EUA or full authorization submissions?
VERBATIM ANSWER: In all likelihood, we may see a slight resurgence in COVID in the coming weeks and months, so the number of positives should increase. If old patterns hold, we're seeing resurgent omicron BA.2 in Europe. And we're just anticipating, because of past historical patterns, that we'll see that here too.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 resurgence, data collection, authorization submissions
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What special controls are developed for the down-classification of antigen tests from de novo to 510k?
CLARIFIED ANSWER: FDA develops special controls for de novo antigen tests, which include a document outlining the methods, ways, and reasons for down-classifying to a 510k pathway.
VERBATIM QUESTION: What special controls are developed for the down-classification of antigen tests from de novo to 510k?
VERBATIM ANSWER: The first one-- that's a de novo-- we do go into more work, because we write special controls, a document that outlines a method of down-classifying, and ways to down-classify, and reasons to down-classify because of mitigations to a 510k.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Special controls, de novo classification, 510k pathway
REVIEW FLAG: False


#### 3. Guidance on FDA Approval for Manufacturing Site Changes

QA Block 3-1
CLARIFIED QUESTION: Should a test developer notify the FDA of an additional manufacturing site for an authorized test?
CLARIFIED ANSWER: FDA recommends test developers notify them when there are manufacturing site changes. This can be done by emailing the lead reviewer and copying the email address associated with the EUA number.
VERBATIM QUESTION: Should a test developer notify the FDA of an additional manufacturing site for an authorized test?
VERBATIM ANSWER: Yes, we do recommend that test developers notify FDA of manufacturing site changes. And you can do this by sending an email to your lead reviewer, and copy the email address that is specific to your EUA number.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: manufacturing site changes, test developer notifications, EUA process
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: How should a test developer handle questions that are too detailed or specific for the FDA Town Hall?
CLARIFIED ANSWER: If a question is too detailed or specific for the Town Hall, FDA will aim to provide a written response within a few days. If no response is received, follow up via the CDRH EUA templates mailbox.
VERBATIM QUESTION: How should a test developer handle questions that are too detailed or specific for the FDA Town Hall?
VERBATIM ANSWER: Please note, we received some questions that are too detailed or test case-specific that we will not be able to address during today's town hall. For those questions, we will try to send a response in writing within a few days. If you have submitted a question and you do not hear it addressed today, please look for a written response. If you do not receive a response within a few days, please feel free to reach back out to the CDRH EUA templates mailbox. So that's CDRH-EUA-Templates@fda.hhs.gov for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: FDA response to detailed questions, CDRH EUA templates mailbox, written follow-up procedures
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: How can a test developer follow up if they do not receive a response from the CDRH EUA templates email?
CLARIFIED ANSWER: If a test developer does not receive a response within a few days, they can follow up by emailing the CDRH-EUA-Templates@fda.hhs.gov mailbox for an update.
VERBATIM QUESTION: How can a test developer follow up if they do not receive a response from the CDRH EUA templates email?
VERBATIM ANSWER: If you have submitted a question and you do not hear it addressed today, please look for a written response. If you do not receive a response within a few days, please feel free to reach back out to the CDRH EUA templates mailbox. So that's CDRH-EUA-Templates@fda.hhs.gov for an update.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: FDA follow-up process, EUA template communication
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: What is the specific email address related to the EUA number that test developers should copy when notifying the FDA of manufacturing site changes?
CLARIFIED ANSWER: To notify FDA of manufacturing site changes, email your lead reviewer and copy the email address associated with your EUA number.
VERBATIM QUESTION: What is the specific email address related to the EUA number that test developers should copy when notifying the FDA of manufacturing site changes?
VERBATIM ANSWER: You can do this by sending an email to your lead reviewer, and copy the email address that is specific to your EUA number.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: manufacturing site changes, EUA notification process
REVIEW FLAG: False


#### 4. EUA Requirements for COVID-19 Serology Tests

QA Block 4-1
CLARIFIED QUESTION: Do laboratory-based qualitative serology tests require an EUA?
CLARIFIED ANSWER: FDA generally expects laboratory-based qualitative serology tests to obtain an EUA or a traditional marketing authorization, such as a granted de novo or cleared 510k, before clinical use. Refer to the November 15, 2021 update to the COVID-19 test policy guidance for more details.
VERBATIM QUESTION: Do laboratory-based qualitative serology tests require an EUA?
VERBATIM ANSWER: Yes. FDA does generally expect newly offered COVID-19 tests, including LDTs, to have an EUA or a traditional marketing authorization, such as a granted de novo or a cleared 510k, prior to clinical use. And you can refer to the November 15, 2021 update to the COVID-19 test policy guidance for additional details. And that is linked on the slides that is showing right now.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA requirements, COVID-19 serology tests, FDA guidance
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: What does the FDA mean by 'traditional marketing authorization' in the context of COVID-19 tests?
CLARIFIED ANSWER: The FDA defines 'traditional marketing authorization' for COVID-19 tests as authorization through a granted de novo or a cleared 510k process.
VERBATIM QUESTION: What does the FDA mean by 'traditional marketing authorization' in the context of COVID-19 tests?
VERBATIM ANSWER: FDA does generally expect newly offered COVID-19 tests, including LDTs, to have an EUA or a traditional marketing authorization, such as a granted de novo or a cleared 510k, prior to clinical use.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: traditional marketing authorization, COVID-19 test approval, FDA regulations
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: Where can developers find the November 15, 2021 update to the COVID-19 test policy guidance?
CLARIFIED ANSWER: Developers can find the November 15, 2021 update to the COVID-19 test policy guidance through the links provided on the slides presented during the session.
VERBATIM QUESTION: Where can developers find the November 15, 2021 update to the COVID-19 test policy guidance?
VERBATIM ANSWER: You can refer to the November 15, 2021 update to the COVID-19 test policy guidance for additional details. And that is linked on the slides that is showing right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: November 15, 2021 COVID-19 test policy update, Developer resources
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: Are there any updates in the November 15, 2021 COVID-19 test policy guidance that affect the EUA process for LDTs?
CLARIFIED ANSWER: Yes, FDA generally expects newly offered COVID-19 tests, including LDTs, to have an EUA or traditional marketing authorization (e.g., a de novo or 510k clearance) before clinical use, as detailed in the November 15, 2021 guidance.
VERBATIM QUESTION: Are there any updates in the November 15, 2021 COVID-19 test policy guidance that affect the EUA process for LDTs?
VERBATIM ANSWER: Yes. FDA does generally expect newly offered COVID-19 tests, including LDTs, to have an EUA or a traditional marketing authorization, such as a granted de novo or a cleared 510k, prior to clinical use. And you can refer to the November 15, 2021 update to the COVID-19 test policy guidance for additional details. And that is linked on the slides that is showing right now.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA process, LDTs, November 2021 COVID-19 test policy
REVIEW FLAG: False


#### 5. Reagent Stability for 510k: Clinical Matrix Requirements

QA Block 5-1
CLARIFIED QUESTION: Are reagent stability studies required to be conducted with panels of samples derived from natural clinical matrix to support a 510(k)?
CLARIFIED ANSWER: Yes, FDA requires that reagent stability studies should include spiking negative clinical matrix with inactivated SARS-CoV-2 at three to five times the limit of detection, and they do not recommend using recombinant protein.
VERBATIM QUESTION: Are reagent stability studies required to be conducted with panels of samples derived from natural clinical matrix to support a 510(k)?
VERBATIM ANSWER: Yes. Reagent stability studies should be prepared by spiking negative clinical matrix with inactivated SARS-CoV-2 at an analyte concentration of three to five times LOD, limit of detection. We do not recommend using recombinant protein.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reagent stability studies, natural clinical matrix, 510(k) support
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: What analyte concentration range should be used for spiking negative clinical matrices in reagent stability studies?
CLARIFIED ANSWER: The FDA recommends spiking negative clinical matrices with inactivated SARS-CoV-2 at an analyte concentration of three to five times the limit of detection (LOD) for reagent stability studies. Recombinant protein should not be used.
VERBATIM QUESTION: What analyte concentration range should be used for spiking negative clinical matrices in reagent stability studies?
VERBATIM ANSWER: Reagent stability studies should be prepared by spiking negative clinical matrix with inactivated SARS-CoV-2 at an analyte concentration of three to five times LOD, limit of detection. We do not recommend using recombinant protein.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reagent stability studies, analyte concentration, 510k support
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Are recombinant proteins acceptable for reagent stability studies?
CLARIFIED ANSWER: FDA does not recommend the use of recombinant proteins for reagent stability studies.
VERBATIM QUESTION: Are recombinant proteins acceptable for reagent stability studies?
VERBATIM ANSWER: We do not recommend using recombinant protein.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: reagent stability studies, recombinant proteins, 510k submission
REVIEW FLAG: False


#### 6. EUA Transition and Monitoring SARS-CoV-2 Test Performance

QA Block 6-1
CLARIFIED QUESTION: Will FDA accept supplements to existing EUAs after the FDA stops accepting new EUA requests?
CLARIFIED ANSWER: FDA will continue accepting supplements to existing EUAs as long as they remain in effect, which is until the emergency use authorization declaration is terminated.
VERBATIM QUESTION: as discussed in the recent EUA transition guidance, will FDA accept supplements to existing EUAs after the FDA stops accepting new EUA requests?
VERBATIM ANSWER: Unless revoked, EUAs are in effect until the declaration that circumstances exist justifying the authorization of the emergency use of In Vitro Diagnostics for detection and/or diagnosis of COVID-19 is terminated, and should be-- and those EUAs should be maintained in accordance with the conditions of authorization.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA supplements, EUA conditions after new requests stop
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: For authorized tests, will the FDA expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations?
CLARIFIED ANSWER: FDA expects developers to routinely monitor and evaluate the performance impact of SARS-CoV-2 viral mutations for authorized tests, as it is a condition of authorization for EUAs and included in special controls for full marketing authorization through de novo or 510k.
VERBATIM QUESTION: For authorized tests, will the FDA expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations?
VERBATIM ANSWER: Yes. So we do expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations for as long as the test is being offered. This is included as a condition of authorization for all COVID-19 test EUAs. And we also expect this to be done for tests that receive full marketing authorization through a de novo or 510k. And we've included this in the special controls for the COVID-19 molecular test de novo that was granted last year.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 viral mutations, test performance monitoring, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What are the conditions of authorization that must be maintained for COVID-19 test EUAs?
CLARIFIED ANSWER: Developers must routinely monitor and evaluate the impact of SARS-CoV-2 mutations on test performance for as long as the test is offered. This applies to all COVID-19 test EUAs and tests with full marketing authorization.
VERBATIM QUESTION: What are the conditions of authorization that must be maintained for COVID-19 test EUAs?
VERBATIM ANSWER: Yes. So we do expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations for as long as the test is being offered. This is included as a condition of authorization for all COVID-19 test EUAs. And we also expect this to be done for tests that receive full marketing authorization through a de novo or 510k. And we've included this in the special controls for the COVID-19 molecular test de novo that was granted last year.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA conditions, SARS-CoV-2 mutations, COVID-19 test monitoring
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: What steps should developers take if they require further clarity on the transition guidance for emergency use devices?
CLARIFIED ANSWER: FDA recommends submitting comments to the docket for unclear points in the draft transition guidance or emailing the EUA templates mailbox with sufficient details for specific assistance.
VERBATIM QUESTION: What steps should developers take if they require further clarity on the transition guidance for emergency use devices?
VERBATIM ANSWER: Regarding the transition guidance, transition plan for medical devices issued EUAs during the COVID-19 public health emergency-- that has been issued in draft for comment, and not for implementation. If there are points about the guidance that are unclear, we recommend that you submit a comment to the docket indicating areas that could benefit from added clarity. And if you have questions about how to manage your current plans for moving forward now with your emergency use test or with the 510k, please send an email to the EUA templates mailbox with sufficient details so that we can provide appropriate feedback.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Transition guidance clarity, EUA transition process
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: How should developers provide sufficient details when contacting the EUA templates mailbox for feedback on their plans?
CLARIFIED ANSWER: Developers should send an email to the EUA templates mailbox with detailed information about their current plans to receive appropriate feedback from the FDA.
VERBATIM QUESTION: How should developers provide sufficient details when contacting the EUA templates mailbox for feedback on their plans?
VERBATIM ANSWER: If you have questions about how to manage your current plans for moving forward now with your emergency use test or with the 510k, please send an email to the EUA templates mailbox with sufficient details so that we can provide appropriate feedback.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA feedback, developer plans, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 6-7
CLARIFIED QUESTION: Is the FDA currently accepting 510k submissions for molecular COVID-19 tests?
CLARIFIED ANSWER: The FDA has cleared a 510k for COVID-19 molecular tests and is accepting additional 510k submissions for such tests.
VERBATIM QUESTION: Is the FDA currently accepting 510k submissions for molecular COVID-19 tests?
VERBATIM ANSWER: And notably, as Tim discussed as well, we have granted a de novo and cleared a 510k for COVID-19 molecular tests, and we welcome additional 510k submissions for molecular tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k submissions, COVID-19 molecular tests, FDA authorization
REVIEW FLAG: False

QA Block 6-8
CLARIFIED QUESTION: What is the FDA's plan for granting full marketing authorization for COVID-19 antigen or serology tests?
CLARIFIED ANSWER: The FDA has not yet granted full marketing authorization for antigen or serology tests but is interested in doing so. A de novo submission would be the first step for these tests.
VERBATIM QUESTION: What is the FDA's plan for granting full marketing authorization for COVID-19 antigen or serology tests?
VERBATIM ANSWER: And while we have not yet granted full marketing authorization for antigen or serology tests, we are interested in doing so, and a de novo would be the first step for each of those.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Full marketing authorization, COVID-19 antigen tests, Serology tests
REVIEW FLAG: False

QA Block 6-9
CLARIFIED QUESTION: What is the process for submitting a comment to the docket if there are unclear aspects in the transition plan guidance?
CLARIFIED ANSWER: The FDA recommends submitting a comment to the docket to highlight unclear areas in the transition guidance, issued in draft for comment. Additional questions about current plans can be emailed to the EUA templates mailbox with details for feedback.
VERBATIM QUESTION: What is the process for submitting a comment to the docket if there are unclear aspects in the transition plan guidance?
VERBATIM ANSWER: Regarding the transition guidance, transition plan for medical devices issued EUAs during the COVID-19 public health emergency-- that has been issued in draft for comment, and not for implementation. If there are points about the guidance that are unclear, we recommend that you submit a comment to the docket indicating areas that could benefit from added clarity. And if you have questions about how to manage your current plans for moving forward now with your emergency use test or with the 510k, please send an email to the EUA templates mailbox with sufficient details so that we can provide appropriate feedback.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Submission process for unclear guidance, Transition guidance for EUAs
REVIEW FLAG: False


#### 7. Evaluating COVID-19 Tests for Stealth Omicron Variant

QA Block 7-1
CLARIFIED QUESTION: Do test developers need to evaluate the stealth omicron variant?
CLARIFIED ANSWER: Yes, FDA expects test developers to evaluate all relevant variants, including BA.2 (also referred to as the stealth omicron variant), as it accounted for about 23% of COVID-19 cases in the U.S. during early March. Developers should assess the prevalence of viral mutations using databases like GISAID, focusing on mutations at a significant frequency (greater than 5%). For specific test-related inquiries, FDA recommends consulting with their reviewer.
VERBATIM QUESTION: Do test developers need to evaluate the stealth omicron variant?
VERBATIM ANSWER: Yes. We expect developers to evaluate the impact of all relevant variants. The BA.2 variant-- which some have referred to as the stealth omicron, since it does not have an S-gene dropout-- has accounted for about 23% of COVID-19 cases in the U.S. from March 6 through 12, according to the CDC. We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And we currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter. And additional discussion about that can be seen in the viral mutations guidance. And if you have specific questions about your test or about evaluation of specific variants, we recommend that you discuss that with your reviewer.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: stealth omicron variant, test evaluation, FDA recommendations
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: What is currently considered a significant frequency for mutations observed in sequence databases?
CLARIFIED ANSWER: A significant frequency for mutations in sequence databases is defined as greater than 5%, based on at least 2,000 sequences over a recent time frame such as the past week, month, or quarter.
VERBATIM QUESTION: What is currently considered a significant frequency for mutations observed in sequence databases?
VERBATIM ANSWER: We currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mutation frequency, variant evaluation, sequence databases
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: Should developers consult the viral mutations guidance for additional details?
CLARIFIED ANSWER: Yes, developers should consult the viral mutations guidance for further details.
VERBATIM QUESTION: Should developers consult the viral mutations guidance for additional details?
VERBATIM ANSWER: And additional discussion about that can be seen in the viral mutations guidance.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: viral mutations guidance, test developer recommendations
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What steps should be taken if developers have specific questions about their test or evaluation of specific variants?
CLARIFIED ANSWER: Developers with specific questions about their test or the evaluation of specific variants should discuss these with their FDA reviewer.
VERBATIM QUESTION: What steps should be taken if developers have specific questions about their test or evaluation of specific variants?
VERBATIM ANSWER: And if you have specific questions about your test or about evaluation of specific variants, we recommend that you discuss that with your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: developer inquiries, variant evaluation, FDA reviewer
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What steps should developers follow to evaluate the impact of the BA.2 variant?
CLARIFIED ANSWER: FDA recommends evaluating BA.2 impact by analyzing viral mutations from sequence databases like GISAID. Focus on mutations that occur at a significant frequency (over 5% among at least 2,000 sequences) within a recent timeframe. Consult the viral mutations guidance or your reviewer for further details.
VERBATIM QUESTION: What steps should developers follow to evaluate the impact of the BA.2 variant?
VERBATIM ANSWER: We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And we currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter. And additional discussion about that can be seen in the viral mutations guidance. And if you have specific questions about your test or about evaluation of specific variants, we recommend that you discuss that with your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: BA.2 variant evaluation, sequence database analysis, mutation prevalence thresholds
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: How should developers use the GISAID database to assess the prevalence of mutations?
CLARIFIED ANSWER: FDA recommends that developers use sequence databases, like GISAID, to assess mutation prevalence, considering mutations significant if found in over 5% of 2,000 sequences within a recent timeframe (week, month, or quarter).
VERBATIM QUESTION: How should developers use the GISAID database to assess the prevalence of mutations?
VERBATIM ANSWER: We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And we currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: GISAID database, mutation frequency, COVID-19 variants
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: What does the FDA consider a significant frequency for mutations in sequence databases in relation to BA.2?
CLARIFIED ANSWER: The FDA considers a significant mutation frequency to be greater than 5% when evaluating at least 2,000 sequences over a recent period, such as a week, month, or quarter.
VERBATIM QUESTION: What does the FDA consider a significant frequency for mutations in sequence databases in relation to BA.2?
VERBATIM ANSWER: We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And we currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: significant mutation frequency, BA.2 variant, sequence database evaluation
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: What time frame is recommended for evaluating mutation prevalence in sequence databases?
CLARIFIED ANSWER: FDA recommends evaluating viral mutation prevalence in databases like GISAID over a period of the past week, month, or quarter, using at least 2,000 sequences.
VERBATIM QUESTION: What time frame is recommended for evaluating mutation prevalence in sequence databases?
VERBATIM ANSWER: We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And we currently consider a significant frequency to be greater than 5% when considered-- when considering at least 2,000 sequences over a recent period of time, such as the past week, month, or quarter.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mutation prevalence, sequence databases, time frame
REVIEW FLAG: False

QA Block 7-9
CLARIFIED QUESTION: Where can developers find further details about mutation evaluation methods?
CLARIFIED ANSWER: Developers can find details about mutation evaluation methods in the viral mutations guidance and by assessing databases like GISAID. Further discussions with the assigned reviewer are also recommended for specific queries.
VERBATIM QUESTION: Where can developers find further details about mutation evaluation methods?
VERBATIM ANSWER: We recommend assessing the prevalence of viral mutations in sequence databases, such as the GISAID database, as mutations observed in these databases at a significant frequency may signify that the mutation is present in an increasing proportion of infected individuals in the U.S. And additional discussion about that can be seen in the viral mutations guidance. And if you have specific questions about your test or about evaluation of specific variants, we recommend that you discuss that with your reviewer.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: mutation evaluation, variant analysis
REVIEW FLAG: False


#### 8. NIH ITAP Program Status and Recent EUA Authorizations

QA Block 8-2
CLARIFIED QUESTION: Have there been any recent EUA authorizations through the NIH ITAP program?
CLARIFIED ANSWER: The NIH ITAP program remains active, and all EUA authorizations are posted on the FDA's website after being granted.
VERBATIM QUESTION: Have there been any recent EUA authorizations through the NIH ITAP program?
VERBATIM ANSWER: Yes, the NIH ITAP program-- the Independent Test Assessment Program-- is still active. We have added the link for that program to the slide that is showing now. If developers are interested in the ITAP program, they can reach out directly through that link. And all EUA authorizations are posted to our website following authorization.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NIH ITAP program, EUA authorizations
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: Where can developers find the link to the NIH ITAP program?
CLARIFIED ANSWER: FDA has added a link to the NIH ITAP program on their current slide. Developers can use this link to reach out for program participation.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Yes, the NIH ITAP program-- the Independent Test Assessment Program-- is still active. We have added the link for that program to the slide that is showing now. If developers are interested in the ITAP program, they can reach out directly through that link. And all EUA authorizations are posted to our website following authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NIH ITAP program, EUA authorizations
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Where are EUA authorizations posted after approval?
CLARIFIED ANSWER: EUA authorizations are posted on the FDA's website after approval.
VERBATIM QUESTION: Where are EUA authorizations posted after approval?
VERBATIM ANSWER: All EUA authorizations are posted to our website following authorization.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA authorizations, FDA website
REVIEW FLAG: False


#### 10. Requirements for Test Result Reporting in 510k Authorization

QA Block 10-1
CLARIFIED QUESTION: Is there a necessity that results reporting will be required when companies convert to a full 510k authorization?
CLARIFIED ANSWER: FDA encourages reporting mechanisms for home tests due to their public health benefit, but there is no requirement for result reporting in full 510k authorizations, including for molecular 510ks under de novo classifications.
VERBATIM QUESTION: Is there a necessity that results reporting will be required when companies convert to a full 510k authorization?
VERBATIM ANSWER: It's not something that I know right now we would advise. I know what we would want is that, because we are asking for connectivity, at least result reporting options for point of care and for at-home tests, that we would hope that those would be carried out into the full authorizations as well, given the public health importance of seeing that. We haven't authorized under full marketing authorization a home test for COVID yet. And lab-based tests-- the lab is recorded-- is required to report. So the reporting for the labs is required under provisions that FDA is not responsible for. And we do encourage for home tests that reporting be built in. It is not required reporting under the same provisions as lab-based reporting, but it is very beneficial for public health, and we would continue to encourage that reporting mechanisms be built in for home tests. If you take a look at the special controls for the molecular 510k from BioFire that was granted last year, there is no mention of reporting in those special controls. So at least for that-- for 510ks under that de novo, there's no requirement placed by FDA, at least.
SPEAKER QUESTION: Phil Groom
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: 510k authorization, result reporting, home test reporting
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: If results reporting is required under a full 510k authorization, will companies need to provide a mobile phone app or website to users?
CLARIFIED ANSWER: FDA has not yet authorized a home test under full marketing authorization, and lab-based test reporting is mandated under external provisions. FDA encourages but does not require reporting mechanisms for home tests, as it benefits public health.
VERBATIM QUESTION: If results reporting is required under a full 510k authorization, will companies need to provide a mobile phone app or website to users?
VERBATIM ANSWER: Yeah. So we haven't authorized under full marketing authorization a home test for COVID yet. And lab-based tests-- the lab is recorded-- is required to report. So the reporting for the labs is required under provisions that FDA is not responsible for. And we do encourage for home tests that reporting be built in. It is not required reporting under the same provisions as lab-based reporting, but it is very beneficial for public health, and we would continue to encourage that reporting mechanisms be built in for home tests.
SPEAKER QUESTION: Phil Groom
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 510k requirements, Test result reporting, Public health
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Does the FDA require connectivity for point-of-care and at-home tests as part of full authorization?
CLARIFIED ANSWER: The FDA encourages result reporting options for point-of-care and at-home tests, hoping these connectivity features are carried into full authorizations for public health benefits.
VERBATIM QUESTION: Does the FDA require connectivity for point-of-care and at-home tests as part of full authorization?
VERBATIM ANSWER: I know what we would want is that, because we are asking for connectivity, at least result reporting options for point of care and for at-home tests, that we would hope that those would be carried out into the full authorizations as well, given the public health importance of seeing that.
SPEAKER QUESTION: Phil Groom
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: connectivity requirements, point-of-care tests, at-home testing
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What are the FDA's expectations for incorporating voluntary reporting mechanisms for home tests?
CLARIFIED ANSWER: The FDA strongly encourages reporting mechanisms to be incorporated into home tests as these are beneficial for public health, although such reporting is not mandated as with lab-based tests.
VERBATIM QUESTION: What are the FDA's expectations for incorporating voluntary reporting mechanisms for home tests?
VERBATIM ANSWER: We do encourage for home tests that reporting be built in. It is not required reporting under the same provisions as lab-based reporting, but it is very beneficial for public health, and we would continue to encourage that reporting mechanisms be built in for home tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: home test reporting, voluntary mechanisms, public health benefit
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Are there specific requirements for lab-based reporting that differ from home-based test reporting?
CLARIFIED ANSWER: Lab-based testing has mandatory reporting requirements under provisions outside of FDA's authority, while home-based tests are not required to report under these provisions. However, FDA strongly encourages incorporating reporting mechanisms in home tests for public health benefits.
VERBATIM QUESTION: Are there specific requirements for lab-based reporting that differ from home-based test reporting?
VERBATIM ANSWER: And lab-based tests-- the lab is recorded-- is required to report. So the reporting for the labs is required under provisions that FDA is not responsible for. And we do encourage for home tests that reporting be built in. It is not required reporting under the same provisions as lab-based reporting, but it is very beneficial for public health, and we would continue to encourage that reporting mechanisms be built in for home tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Lab test reporting, Home test reporting, Reporting requirements
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: Do the special controls for molecular 510k devices require test result reporting or connectivity features?
CLARIFIED ANSWER: The FDA does not require reporting features in the special controls for molecular 510k devices, as demonstrated by the BioFire authorization.
VERBATIM QUESTION: Do the special controls for molecular 510k devices require test result reporting or connectivity features?
VERBATIM ANSWER: If you take a look at the special controls for the molecular 510k from BioFire that was granted last year, there is no mention of reporting in those special controls. So at least for that-- for 510ks under that de novo, there's no requirement placed by FDA, at least.
SPEAKER QUESTION: Phil Groom
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: 510k devices, test result reporting, FDA special controls
REVIEW FLAG: False


#### 11. Using OTC Studies for POC Submissions and Resubmissions

QA Block 11-1
CLARIFIED QUESTION: Could we use a completed clinical study from a home test submission for a point of care EUA submission?
CLARIFIED ANSWER: Yes, a completed clinical study from a home test submission can be used for a point of care EUA submission, especially since OTC studies often fulfill point of care requirements if the test performs well and necessary supporting studies are completed.
VERBATIM QUESTION: Could we use a completed clinical study from a home test submission for a point of care EUA submission?
VERBATIM ANSWER: Yes. In short, yes. And in fact, we do recommend that those developers who are willing to take a risk-- we encourage the risk to go right to OTC studies, because if we issue an EUA for an OTC test, it automatically qualifies for a point of care without having to do any point of care studies-- specific studies. All the studies that would-- that are important for point of care, are down there right with-- for the OTC version. It does save effort to do that. As long as the test performs fine in that OTC setting and all the other studies are done to support that, then that's fine. And we'd be happy to issue both a OTC version and a professional version of the test with-- solely with the OTC studies.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Use of OTC studies, Point of care diagnostics
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Could we include the OTC study in a POC submission while also submitting an OTC request?
CLARIFIED ANSWER: Yes, an OTC study can be used to support the point of care (POC) version of the test.
VERBATIM QUESTION: Could we include the OTC study in a POC submission while also submitting an OTC request?
VERBATIM ANSWER: Yeah. That's what I was trying to say, that you can use the OTC study to support the point of care version of the test.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC study in POC submission, EUA requests
REVIEW FLAG: False

QA Block 11-4
CLARIFIED QUESTION: Can a rejected EUA submission be resubmitted as a brand new request after fixing issues?
CLARIFIED ANSWER: Yes, a rejected EUA submission can be resubmitted as a new request after fixing the identified issues, but the FDA requires detailed responses addressing their prior concerns.
VERBATIM QUESTION: Can a rejected EUA submission be resubmitted as a brand new request after fixing issues?
VERBATIM ANSWER: Yes. Yeah. So we have a number of decline letters, depending on the specific situation. But if we issued either what's called a refuse to accept because the application wasn't complete in some way or we issued a decline to issue letter-- and the specific words are used in those letters, even though it's a little bit hard to sometimes decipher-- but if we had issues with the submission and provided feedback, and then, when we-- if we got a response, if it was inadequate, we would have gone ahead and declined to issue. But yes, if you later on are able to address all our concerns, you're welcome to resubmit. And we would ask that you specifically address those concerns based on our prior communication with you specifically so we can determine whether or not you have addressed all of these issues.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA resubmission process, Addressing prior feedback
REVIEW FLAG: False

QA Block 11-5
CLARIFIED QUESTION: Does an OTC study automatically fulfill the requirements for a point of care (POC) EUA test if approved?
CLARIFIED ANSWER: Yes, an OTC study automatically qualifies for a point of care EUA if the test performs well in the OTC setting and all required studies are completed. FDA often issues both OTC and professional test versions based on OTC studies.
VERBATIM QUESTION: Does an OTC study automatically fulfill the requirements for a point of care (POC) EUA test if approved?
VERBATIM ANSWER: Yes. In short, yes. And in fact, we do recommend that those developers who are willing to take a risk-- we encourage the risk to go right to OTC studies, because if we issue an EUA for an OTC test, it automatically qualifies for a point of care without having to do any point of care studies-- specific studies. All the studies that would-- that are important for point of care, are down there right with-- for the OTC version. It does save effort to do that. As long as the test performs fine in that OTC setting and all the other studies are done to support that, then that's fine. And we'd be happy to issue both a OTC version and a professional version of the test with-- solely with the OTC studies.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC study for POC EUA, EUA requirements, Point of care testing
REVIEW FLAG: False

QA Block 11-6
CLARIFIED QUESTION: What criteria need to be met for an OTC submission to also qualify for a professional version EUA?
CLARIFIED ANSWER: If an EUA is issued for an OTC test, it automatically qualifies for a point of care use without specific POC studies, provided the test performs well in the OTC setting and all necessary studies are completed.
VERBATIM QUESTION: What criteria need to be met for an OTC submission to also qualify for a professional version EUA?
VERBATIM ANSWER: And in fact, we do recommend that those developers who are willing to take a risk-- we encourage the risk to go right to OTC studies, because if we issue an EUA for an OTC test, it automatically qualifies for a point of care without having to do any point of care studies-- specific studies. All the studies that would-- that are important for point of care, are down there right with-- for the OTC version. It does save effort to do that. As long as the test performs fine in that OTC setting and all the other studies are done to support that, then that's fine. And we'd be happy to issue both a OTC version and a professional version of the test with-- solely with the OTC studies.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC and POC EUA criteria, Test performance requirements
REVIEW FLAG: False

QA Block 11-7
CLARIFIED QUESTION: If a kit is used for both OTC and POC, what specific variable factors should be addressed in testing?
CLARIFIED ANSWER: FDA suggests conducting guard band testing to evaluate variability factors, such as time variations, for a kit used in both OTC and POC testing. Submissions should link data via cover letters and explain reasons for excluding clinical study data.
VERBATIM QUESTION: If a kit is used for both OTC and POC, what specific variable factors should be addressed in testing?
VERBATIM ANSWER: You would have also done guard band testing for variable factors. I don't know if you did find a duplicate. It's probably a single kit used for both. How much can the time varywhen you're running tests. So just to make sure that, when you submit one or the other, or both at the same time, you provide cover letters that explain the relationship, and in the point of care submission, that you explain, that you're submitting all the point of care data that you collected except for the clinical study. And the reasons why you're not submitting the clinical study data-- typically, if you perform studies, especially correctly, we want to see the data nevertheless.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC/POC variable testing, Guard band testing, Submission protocols
REVIEW FLAG: False

QA Block 11-8
CLARIFIED QUESTION: What information should be included in the cover letters when submitting linked OTC and POC submissions?
CLARIFIED ANSWER: The cover letters should explain the relationship between the OTC and POC submissions. In the POC submission, explain that all point-of-care data (except the clinical study) is being submitted, with reasons for not submitting clinical study data, if applicable.
VERBATIM QUESTION: What information should be included in the cover letters when submitting linked OTC and POC submissions?
VERBATIM ANSWER: So just to make sure that, when you submit one or the other, or both at the same time, you provide cover letters that explain the relationship, and in the point of care submission, that you explain, that you're submitting all the point of care data that you collected except for the clinical study. And the reasons why you're not submitting the clinical study data-- typically, if you perform studies, especially correctly, we want to see the data nevertheless.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: cover letter requirements, EUA submissions, OTC and POC relationship
REVIEW FLAG: False

QA Block 11-9
CLARIFIED QUESTION: How should a developer justify not submitting POC clinical study data while addressing operator-specific questions in the same submission?
CLARIFIED ANSWER: FDA advises developers to explain why POC clinical study data is not being submitted and provide cover letters linking submissions. Developers should clarify that all POC data except the clinical study is included.
VERBATIM QUESTION: How should a developer justify not submitting POC clinical study data while addressing operator-specific questions in the same submission?
VERBATIM ANSWER: Yeah, just explain everything in your submission. You can make two separate submissions, but do tell us that the two submissions are linked via the clinical study. You would have also done guard band testing for variable factors. I don't know if you did find a duplicate. It's probably a single kit used for both. How much can the time varywhen you're running tests. So just to make sure that, when you submit one or the other, or both at the same time, you provide cover letters that explain the relationship, and in the point of care submission, that you explain, that you're submitting all the point of care data that you collected except for the clinical study. And the reasons why you're not submitting the clinical study data-- typically, if you perform studies, especially correctly, we want to see the data nevertheless.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: POC submission justification, Operator-specific data, Linking submissions
REVIEW FLAG: False

QA Block 11-10
CLARIFIED QUESTION: Is it necessary to include guard band testing results in EUA submissions for tests used in both OTC and POC settings?
CLARIFIED ANSWER: Guard band testing for variable factors should be conducted and included in EUA submissions. Provide cover letters explaining the relationship between OTC and POC submissions, and include all collected POC data except for the clinical study, with reasons noted.
VERBATIM QUESTION: Is it necessary to include guard band testing results in EUA submissions for tests used in both OTC and POC settings?
VERBATIM ANSWER: You would have also done guard band testing for variable factors. I don't know if you did find a duplicate. It's probably a single kit used for both. How much can the time varywhen you're running tests. So just to make sure that, when you submit one or the other, or both at the same time, you provide cover letters that explain the relationship, and in the point of care submission, that you explain, that you're submitting all the point of care data that you collected except for the clinical study. And the reasons why you're not submitting the clinical study data-- typically, if you perform studies, especially correctly, we want to see the data nevertheless.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, Guard band testing, OTC and POC relationship
REVIEW FLAG: False

QA Block 11-11
CLARIFIED QUESTION: How should feedback from a prior declined EUA submission be incorporated into a resubmission?
CLARIFIED ANSWER: If an EUA submission is declined, applicants may resubmit if they address all the concerns mentioned in the feedback, following the FDA's prior communication on the issues.
VERBATIM QUESTION: How should feedback from a prior declined EUA submission be incorporated into a resubmission?
VERBATIM ANSWER: So we have a number of decline letters, depending on the specific situation. But if we issued either what's called a refuse to accept because the application wasn't complete in some way or we issued a decline to issue letter-- and the specific words are used in those letters, even though it's a little bit hard to sometimes decipher-- but if we had issues with the submission and provided feedback, and then, when we-- if we got a response, if it was inadequate, we would have gone ahead and declined to issue. But yes, if you later on are able to address all our concerns, you're welcome to resubmit. And we would ask that you specifically address those concerns based on our prior communication with you specifically so we can determine whether or not you have addressed all of these issues.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA feedback incorporation, Resubmission requirements
REVIEW FLAG: False


#### 12. Mitigating Risks in Combined Usability and Clinical Studies

QA Block 12-2
CLARIFIED QUESTION: Can potential training bias in a combined usability and clinical agreement study be mitigated by having the subject conduct the clinical agreement study portion of the test first and then the usability study?
CLARIFIED ANSWER: The FDA agrees that conducting the clinical study followed by the usability study can help mitigate potential training bias and save time and resources, with no significant issues anticipated if the risk is acceptable.
VERBATIM QUESTION: Can potential training bias in a combined usability and clinical agreement study be mitigated by having the subject conduct the clinical agreement study portion of the test first and then the usability study?
VERBATIM ANSWER: Thank you for appreciating the potential for bias and doing the clinical study first, and then the usability-- to show the usability of the test seems fine. I know of no issues why you can't take that risk if you're willing to, because it obviously does save time and resources to do that.
SPEAKER QUESTION: James Mullally
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: training bias, study sequence, usability and clinical agreement
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: Does the FDA foresee other challenges in a combined usability and clinical agreement study, such as identification of significant issues that could render the clinical study null and void?
CLARIFIED ANSWER: The FDA sees the main risk as the usability study identifying necessary modifications, such as significant changes to workload instructions, which could invalidate the clinical study. Conducting the clinical study first to mitigate bias is acceptable if the sponsor is prepared to take that risk, as it saves time and resources.
VERBATIM QUESTION: Does the FDA foresee other challenges in a combined usability and clinical agreement study, such as identification of significant issues that could render the clinical study null and void?
VERBATIM ANSWER: So the main risk, Jim, is that you find out in usability study that you have to modify something. Right? Workload instructions that are significant that would invalidate the clinical study. Thank you for appreciating the potential for bias and doing the clinical study first, and then the usability-- to show the usability of the test seems fine. I know of no issues why you can't take that risk if you're willing to, because it obviously does save time and resources to do that.
SPEAKER QUESTION: James Mullally
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: combined usability and clinical studies, risk of invalidating studies, mitigating training bias
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: Should labeling changes be required in the case of significant issues during a combined usability and clinical agreement study, and how does this impact the study?
CLARIFIED ANSWER: The main risk is finding significant issues during the usability study, such as needing to modify workload instructions, which could invalidate the clinical study. Conducting the clinical study first, followed by the usability study, could mitigate bias and is an acceptable approach to save time and resources.
VERBATIM QUESTION: Should labeling changes be required in the case of significant issues during a combined usability and clinical agreement study, and how does this impact the study?
VERBATIM ANSWER: So the main risk, Jim, is that you find out in usability study that you have to modify something. Right? Workload instructions that are significant that would invalidate the clinical study. Thank you for appreciating the potential for bias and doing the clinical study first, and then the usability- - to show the usability of the test seems fine. I know of no issues why you can't take that risk if you're willing to, because it obviously does save time and resources to do that.
SPEAKER QUESTION: James Mullally
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Labeling changes, Usability study risks, Study protocol strategy
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What risks does the FDA associate with making modifications to workload instructions after beginning a clinical study?
CLARIFIED ANSWER: FDA associates the risk of significant modifications to workload instructions with rendering the clinical study invalid.
VERBATIM QUESTION: What risks does the FDA associate with making modifications to workload instructions after beginning a clinical study?
VERBATIM ANSWER: Workload instructions that are significant that would invalidate the clinical study.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Modification risks, Workload instructions, Clinical study validity
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: Can conducting a mini usability or mini clinical study mitigate risks for developers of new diagnostic tests entering the U.S. market?
CLARIFIED ANSWER: Conducting mini usability or clinical studies might mitigate risks, especially for new tests being introduced to the U.S. However, it is not required or explicitly recommended by the FDA.
VERBATIM QUESTION: Can conducting a mini usability or mini clinical study mitigate risks for developers of new diagnostic tests entering the U.S. market?
VERBATIM ANSWER: First of all, if the test has been launched outside the U.S. and you have a lot of experience already with it, and it works fine, the risks may be lower. But if this is a brand new test-- you're coming first to the U.S., say-- and you don't have as much experience, then you may want to do some mini usability, mini clinical study to make sure that performance with those instructions is decent on a very small subset of users, even company personnel, just to verify that everything's-- that would mitigate some of the risk, obviously, if you did something that. But it's not required, not necessarily even recommended. It's just
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: mini usability studies, risk mitigation, new diagnostics
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: Is it advisable to test on a small subset of users, like company personnel, before embarking on a large-scale study, even though it is not required?
CLARIFIED ANSWER: FDA suggests that testing a small subset of users, such as company personnel, may help mitigate risks for new tests, but it is not required or formally recommended.
VERBATIM QUESTION: Is it advisable to test on a small subset of users, like company personnel, before embarking on a large-scale study, even though it is not required?
VERBATIM ANSWER: Yeah, I'm just telling you what-- if I was in your all's shoes, what I would do. First of all, if the test has been launched outside the U.S. and you have a lot of experience already with it, and it works fine, the risks may be lower. But if this is a brand new test-- you're coming first to the U.S., say-- and you don't have as much experience, then you may want to do some mini usability, mini clinical study to make sure that performance with those instructions is decent on a very small subset of users, even company personnel, just to verify that everything's-- that would mitigate some of the risk, obviously, if you did something that. But it's not required, not necessarily even recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Testing small subsets, Risk mitigation, Study preparation
REVIEW FLAG: False

QA Block 12-9
CLARIFIED QUESTION: Are there alternative approaches to mitigate risks in a combined usability and clinical agreement study if the test is new to the U.S. and lacks extensive prior use?
CLARIFIED ANSWER: FDA suggests conducting small-scale usability and clinical studies for a new test in the U.S. to verify performance and reduce risks, though this is not required or explicitly recommended.
VERBATIM QUESTION: Are there alternative approaches to mitigate risks in a combined usability and clinical agreement study if the test is new to the U.S. and lacks extensive prior use?
VERBATIM ANSWER: First of all, if the test has been launched outside the U.S. and you have a lot of experience already with it, and it works fine, the risks may be lower. But if this is a brand new test-- you're coming first to the U.S., say-- and you don't have as much experience, then you may want to do some mini usability, mini clinical study to make sure that performance with those instructions is decent on a very small subset of users, even company personnel, just to verify that everything's-- that would mitigate some of the risk, obviously, if you did something that. But it's not required, not necessarily even recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: risk mitigation, usability and clinical study, performance verification
REVIEW FLAG: False


#### 13. Guidance on Omicron Sequencing for EUA Resubmissions

QA Block 13-1
CLARIFIED QUESTION: If we resubmit using data from a previous submission, can we use 10 positive sequences for sequencing, or do we need to provide more than 10, such as 30 plus additional positives?
CLARIFIED ANSWER: For resubmission using preexisting omicron data, the FDA requires a minimum of 10 samples to assess performance. If starting anew, sequencing the first 30 positives may be necessary. Discuss specific sequencing requirements with your FDA reviewer.
VERBATIM QUESTION: If we resubmit using data from a previous submission, can we use 10 positive sequences for sequencing, or do we need to provide more than 10, such as 30 plus additional positives?
VERBATIM ANSWER: As far as the sequencing that we have requested, this specifically has to do with omicron and performing-- and assessing performance in omicron, since-- because of some of the challenges that we've seen with omicron. So typically, if a submission has already been in-- and this time period is a little bit past now, because omicron is now obviously on the downswing, they may come up a little bit with BA.2. For submissions that were already in, we were-- in order to speed them through the system, we were asking for a minimum of 10 samples that were from the omicron period to be able to assess performance. We weren't necessarily requesting a sequence analysis on those 10 pre-authorization, but the sequences could be potentially provided after if it was important to timely make the decision on the test. And now, if you're doing the study anew, during the omicron period, we would ask that the positives be sequenced. It may be that you can discuss it with the reviewer, whether it's maybe the first 30 positives, and-- if there's challenges with getting sequencing back in a timely manner, and we have a subset, that's something else you can discuss with your reviewer as well. We're just trying to establish either pre- market or post-market performance on omicron samples.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Sequencing requirements, Omicron data, EUA resubmission
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: Can we use our previous pre-omicron data for the resubmission?
CLARIFIED ANSWER: You can use some pre-omicron data for the resubmission, but the FDA requires omicron data to be included.
VERBATIM QUESTION: Can we use our previous pre-omicron data for the resubmission?
VERBATIM ANSWER: And I would add that, if your clinical study was pre-omicron, we do want to see omicron data, so include that in the submission, whatever you have.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: using pre-omicron data, omicron data requirements, resubmission criteria
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: Can we contact our previously assigned lead reviewer to ask specific questions about the submission if the project was closed?
CLARIFIED ANSWER: You can contact your previously assigned lead reviewer, but the FDA prefers to have a new submission on file before starting the conversation.
VERBATIM QUESTION: Can we contact our previously assigned lead reviewer to ask specific questions about the submission if the project was closed?
VERBATIM ANSWER: I would say, once you have submitted your EUA, then you could definitely engage with your lead. But we prefer to have a submission on file in order to start that conversation.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: contacting previous reviewer, EUA submission process
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: How should developers ensure that their comparator assays meet FDA requirements?
CLARIFIED ANSWER: FDA recommends developers consult with them to ensure their comparator assays are acceptable high-sensitivity assays before initiating studies.
VERBATIM QUESTION: How should developers ensure that their comparator assays meet FDA requirements?
VERBATIM ANSWER: Yeah, so I'll just take it as an opportunity to remind folks that the FDA does recommend that you check with us about your comparator assay. There are clearly some nuances there. We want to make sure that it's an acceptable high-sensitivity comparator assay ahead of you doing the study so that this sort of thing doesn't happen.
SPEAKER QUESTION: Annie Wright
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator assays, FDA consultation, EUA requirements
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What are the FDA's specific requirements for sequencing omicron samples in new studies?
CLARIFIED ANSWER: The FDA requires sequencing data during new studies on omicron. For older submissions, 10 omicron samples suffice for assessing performance, with sequencing possibly provided later. In new studies, positives must be sequenced, but timelines can be discussed with reviewers.
VERBATIM QUESTION: What are the FDA's specific requirements for sequencing omicron samples in new studies?
VERBATIM ANSWER: As far as the sequencing that we have requested, this specifically has to do with omicron and performing-- and assessing performance in omicron, since-- because of some of the challenges that we've seen with omicron. So typically, if a submission has already been in-- and this time period is a little bit past now, because omicron is now obviously on the downswing, they may come up a little bit with BA.2. For submissions that were already in, we were-- in order to speed them through the system, we were asking for a minimum of 10 samples that were from the omicron period to be able to assess performance. We weren't necessarily requesting a sequence analysis on those 10 pre-authorization, but the sequences could be potentially provided after if it was important to timely make the decision on the test. And now, if you're doing the study anew, during the omicron period, we would ask that the positives be sequenced. It may be that you can discuss it with the reviewer, whether it's maybe the first 30 positives, and-- if there's challenges with getting sequencing back in a timely manner, and we have a subset, that's something else you can discuss with your reviewer as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: omicron sequencing requirements, EUA resubmissions, study performance assessment
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: If sequencing for omicron samples cannot be completed on all samples in a timely manner, how should developers prioritize which samples to sequence?
CLARIFIED ANSWER: Developers should consult with the FDA reviewer to determine if sequencing can be done on the first 30 positive samples or a subset if timely sequencing of all samples is not possible.
VERBATIM QUESTION: If sequencing for omicron samples cannot be completed on all samples in a timely manner, how should developers prioritize which samples to sequence?
VERBATIM ANSWER: It may be that you can discuss it with the reviewer, whether it's maybe the first 30 positives, and-- if there's challenges with getting sequencing back in a timely manner, and we have a subset, that's something else you can discuss with your reviewer as well. We're just trying to establish either pre-market or post-market performance on omicron samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Prioritizing omicron sequencing, EUA submission process
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: Should sequencing data for omicron-positive samples be submitted pre- or post-authorization?
CLARIFIED ANSWER: FDA does not require sequencing data pre-authorization for the 10 omicron-positive samples, but it can be submitted post-authorization to facilitate timely test decisions.
VERBATIM QUESTION: Should sequencing data for omicron-positive samples be submitted pre- or post-authorization?
VERBATIM ANSWER: We weren't necessarily requesting a sequence analysis on those 10 pre-authorization, but the sequences could be potentially provided after if it was important to timely make the decision on the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: omicron sequencing, pre-authorization, test decision timeline
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: Are there alternative strategies for meeting FDA sequencing requirements for omicron samples during times when omicron is predominant?
CLARIFIED ANSWER: FDA advises initiating a dialogue with them for alternative sequencing strategies during the predominant omicron period. Submissions should not be delayed, even if sequencing data is unavailable initially.
VERBATIM QUESTION: Are there alternative strategies for meeting FDA sequencing requirements for omicron samples during times when omicron is predominant?
VERBATIM ANSWER: Yeah. No, I think that's the point. I think we want to have a dialogue about it as we move forward in time. Obviously, omicron is predominant by quite a bit, so there may be other strategies we can take advantage of as well. I'd say don't hold up your submission. If you don't have that sequencing data, submit it and then start that dialogue with us so we can engage with you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Alternative sequencing strategies, Omicron predominant period, Submission process
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: Is it acceptable to submit an EUA without complete sequencing data for omicron, and address the sequencing requirements in post-submission dialogue?
CLARIFIED ANSWER: The FDA advises not to delay an EUA submission due to incomplete sequencing data for omicron. Submit the EUA and initiate dialogue with the FDA to address sequencing requirements.
VERBATIM QUESTION: Is it acceptable to submit an EUA without complete sequencing data for omicron, and address the sequencing requirements in post-submission dialogue?
VERBATIM ANSWER: I'd say don't hold up your submission. If you don't have that sequencing data, submit it and then start that dialogue with us so we can engage with you.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: EUA submission, Sequencing data for omicron, Post-submission dialogue
REVIEW FLAG: False

QA Block 13-10
CLARIFIED QUESTION: What kind of post-market performance data for omicron samples might the FDA expect?
CLARIFIED ANSWER: FDA aims to establish either pre-market or post-market performance data for omicron samples.
VERBATIM QUESTION: What kind of post-market performance data for omicron samples might the FDA expect?
VERBATIM ANSWER: We're just trying to establish either pre-market or post-market performance on omicron samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-market performance data, Omicron samples, FDA requirements
REVIEW FLAG: False


#### 14. Home Molecular Tests Likely Require De Novo Pathway

QA Block 14-1
CLARIFIED QUESTION: Would a home use molecular test be able to use BioFire as a predicate, or would it require a de novo?
CLARIFIED ANSWER: The FDA anticipates that a home use molecular test would likely require a de novo pathway due to differing risks and benefits from other tests, although no official determination has been made.
VERBATIM QUESTION: Would a home use molecular test be able to use BioFire as a predicate, or would it require a de novo?
VERBATIM ANSWER: Yeah. I'm a little bit hesitant to mention for sure that it's going to be a de novo, because we would actually need to have-- to make that determination. But it's highly likely that a home test is going to be following the de novo pathway. The risks are different. The benefits are different. It's a fairly obvious, I think, determination that we can say it ahead of time, but of course, we haven't made it official yet.
SPEAKER QUESTION: Sarai Meyer
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: de novo pathway, home use molecular tests, BioFire predicate
REVIEW FLAG: False


#### 15. Public Health Emergency Declaration and Extension Uncertainty

QA Block 15-1
CLARIFIED QUESTION: Is there any indication presently that the public health emergency (PHE), last signed on January 14 and good for 90 days, is going to be extended or renewed?
CLARIFIED ANSWER: FDA does not have information on whether the 90-day public health emergency will be extended but notes no reason to think the Secretary's declaration would be terminated soon. FDA is working on a transition plan and seeking public input.
VERBATIM QUESTION: Is there any indication presently that the public health emergency (PHE), last signed on January 14 and good for 90 days, is going to be extended or renewed?
VERBATIM ANSWER: So this is what I was mentioning a little bit during one of the questions that came in by email. The issuance of EUA and the EUAs being in effect is based on a declaration by the Secretary of HHS that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19. That declaration is different from the public health emergency that you're referring to. So the declaration by the secretary does not expire. It has to be proactively terminated. And as I mentioned before, the declarations-- the similar declarations for previous public health emergencies, such as Zika and Ebola, have not-- have still not been terminated. So we do not have any information on the timeline of when the declaration that circumstances exist may be terminated, or on the 90-day public health emergency and whether or not that will be extended. But we don't have any reason to believe right now that the secretary's declaration would be terminated any time soon. And we as you've likely seen with the transition guidance that I mentioned earlier, we are actively working towards getting information out and getting public comment on that transition plan.
SPEAKER QUESTION: Stacy Drakousis
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Public Health Emergency extension, Emergency declarations, COVID-19 diagnostics
REVIEW FLAG: False

QA Block 15-2
CLARIFIED QUESTION: What is the difference between the Secretary of HHS's declaration for EUAs and the public health emergency declaration?
CLARIFIED ANSWER: The Secretary of HHS's declaration for EUAs does not expire and must be proactively terminated, whereas the public health emergency declaration is time-limited and subject to renewal.
VERBATIM QUESTION: What is the difference between the Secretary of HHS's declaration for EUAs and the public health emergency declaration?
VERBATIM ANSWER: The issuance of EUA and the EUAs being in effect is based on a declaration by the Secretary of HHS that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19. That declaration is different from the public health emergency that you're referring to. So the declaration by the secretary does not expire. It has to be proactively terminated. And as I mentioned before, the declarations-- the similar declarations for previous public health emergencies, such as Zika and Ebola, have not-- have still not been terminated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Secretary of HHS declaration, EUA issuance, Public health emergency
REVIEW FLAG: False

QA Block 15-3
CLARIFIED QUESTION: Does the Secretary of HHS's declaration for EUAs have an expiration date or other time constraints?
CLARIFIED ANSWER: The HHS Secretary's EUA declaration does not have an expiration date and must be proactively terminated. Similar declarations for other emergencies have remained in effect.
VERBATIM QUESTION: Does the Secretary of HHS's declaration for EUAs have an expiration date or other time constraints?
VERBATIM ANSWER: The issuance of EUA and the EUAs being in effect is based on a declaration by the Secretary of HHS that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19. That declaration is different from the public health emergency that you're referring to. So the declaration by the secretary does not expire. It has to be proactively terminated. And as I mentioned before, the declarations-- the similar declarations for previous public health emergencies, such as Zika and Ebola, have not-- have still not been terminated. So we do not have any information on the timeline of when the declaration that circumstances exist may be terminated, or on the 90-day public health emergency and whether or not that will be extended. But we don't have any reason to believe right now that the secretary's declaration would be terminated any time soon.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: HHS declaration for EUAs, termination conditions, EUA expiration
REVIEW FLAG: False

QA Block 15-4
CLARIFIED QUESTION: What past examples exist of similar declarations (e.g., Zika, Ebola) remaining active beyond the public health emergency?
CLARIFIED ANSWER: The declarations for previous public health emergencies, such as Zika and Ebola, are still active and have not been terminated.
VERBATIM QUESTION: What past examples exist of similar declarations (e.g., Zika, Ebola) remaining active beyond the public health emergency?
VERBATIM ANSWER: And as I mentioned before, the declarations-- the similar declarations for previous public health emergencies, such as Zika and Ebola, have not-- have still not been terminated.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Zika and Ebola declarations, Declaration duration
REVIEW FLAG: False

QA Block 15-5
CLARIFIED QUESTION: What is the status of the transition guidance related to EUAs and how can developers provide feedback?
CLARIFIED ANSWER: The FDA is actively working on sharing information and gathering public feedback on the transition plan for EUAs.
VERBATIM QUESTION: What is the status of the transition guidance related to EUAs and how can developers provide feedback?
VERBATIM ANSWER: And we as you've likely seen with the transition guidance that I mentioned earlier, we are actively working towards getting information out and getting public comment on that transition plan.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: EUA transition guidance, Developer feedback
REVIEW FLAG: False


#### 16. Usability Validation and Clinical Studies Sequencing

QA Block 16-1
CLARIFIED QUESTION: Should usability validation be conducted prior to the clinical study to ensure safe and effective use before starting the clinical study?
CLARIFIED ANSWER: The traditional method is to conduct usability validation before the clinical study to allow changes addressing usability concerns. However, the FDA provides flexibility to compress timelines by conducting both simultaneously, though this involves potential risks such as needing to stop or restart the clinical study.
VERBATIM QUESTION: Should usability validation be conducted prior to the clinical study to ensure safe and effective use before starting the clinical study?
VERBATIM ANSWER: Yeah, so that's the traditional way of doing it, right -- to do usability first, and then the clinical study second if everything looks good in the usability. Otherwise, you can make changes to your instructions or device that address any of the potential usability concerns. What the FDA has done for this is to provide flexibility to compress timelines -- and shorten all of this down, and also potentially limit cost. But it does come with a risk, as I mentioned before. It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too. We're just providing that flexibility. It's up to the developer to decide which path they want to take, the traditional or the shortened.
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability validation, clinical study sequencing, FDA flexibility
REVIEW FLAG: False

QA Block 16-2
CLARIFIED QUESTION: Would incorporating a usability survey with pointed questions during the clinical study help demonstrate that the usability and comprehension of the device reflect the same success as the usability validation?
CLARIFIED ANSWER: Incorporating a usability survey during clinical studies to align usability and comprehension with validation success seems logical, but specifics may require direct FDA consultation.
VERBATIM QUESTION: Would incorporating a usability survey with pointed questions during the clinical study help demonstrate that the usability and comprehension of the device reflect the same success as the usability validation?
VERBATIM ANSWER: Yeah, I understand that a little bit better. And that does seem logical. Kris, do you have any additional comments at this time? We're kind of getting into very specifics here, so
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability surveys in clinical studies, validating device usability
REVIEW FLAG: False

QA Block 16-3
CLARIFIED QUESTION: Is it acceptable, in FDA's opinion, to show that the usability perception of the user and the performance in the clinical study reflect the same results from the usability study, especially if there are minor changes that don't require supplemental usability studies?
CLARIFIED ANSWER: FDA acknowledges that it seems logical to show usability results aligning with clinical study results, but specific cases may require direct dialogue with the FDA.
VERBATIM QUESTION: Is it acceptable, in FDA's opinion, to show that the usability perception of the user and the performance in the clinical study reflect the same results from the usability study, especially if there are minor changes that don't require supplemental usability studies?
VERBATIM ANSWER: Yeah, I understand that a little bit better. And that does seem logical. Kris, do you have any additional comments at this time? We're kind of getting into very specifics here, so
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability study, clinical study results, FDA flexibility
REVIEW FLAG: False

QA Block 16-4
CLARIFIED QUESTION: Can data from usability surveys conducted during clinical studies be used as supplemental data to support a statement of safe and effective use?
CLARIFIED ANSWER: FDA acknowledges that it is possible to use data from usability surveys during clinical studies as supplemental data to support a statement of safe and effective use.
VERBATIM QUESTION: Can data from usability surveys conducted during clinical studies be used as supplemental data to support a statement of safe and effective use?
VERBATIM ANSWER: It's a possibility.
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: usability surveys, clinical studies, supplemental data
REVIEW FLAG: False

QA Block 16-6
CLARIFIED QUESTION: What are potential risks for usability testing and clinical studies if conducted simultaneously rather than sequentially?
CLARIFIED ANSWER: Conducting usability testing and clinical studies simultaneously could lead to safety issues requiring the study to be stopped, or discovering later usability concerns that necessitate restarting the clinical study.
VERBATIM QUESTION: What are potential risks for usability testing and clinical studies if conducted simultaneously rather than sequentially?
VERBATIM ANSWER: It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too.
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability testing risks, Clinical studies sequencing, FDA flexibility
REVIEW FLAG: False

QA Block 16-7
CLARIFIED QUESTION: Does the FDA recommend timeline compression for usability validation and clinical studies if it reduces costs despite associated risks?
CLARIFIED ANSWER: The FDA provides flexibility to compress timelines for usability validation and clinical studies, which may reduce costs but involves risks such as study interruption or restart due to safety concerns. Developers can choose between traditional and shortened timelines.
VERBATIM QUESTION: Does the FDA recommend timeline compression for usability validation and clinical studies if it reduces costs despite associated risks?
VERBATIM ANSWER: What the FDA has done for this is to provide flexibility to compress timelines and shorten all of this down, and also potentially limit cost. But it does come with a risk, as I mentioned before. It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too. We're just providing that flexibility. It's up to the developer to decide which path they want to take, the traditional or the shortened.
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: timeline compression, usability validation, cost-risk tradeoff
REVIEW FLAG: False

QA Block 16-8
CLARIFIED QUESTION: In cases where usability testing identifies issues after clinical studies begin, how should developers address these problems without restarting the entire study?
CLARIFIED ANSWER: If usability issues are identified during or after clinical studies, developers might need to stop and restart the study to address these concerns. FDA provides flexibility but warns of associated risks.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability testing, study adjustments, clinical study risks
REVIEW FLAG: False

QA Block 16-9
CLARIFIED QUESTION: What is the FDA's stance on using real-time clinical usability surveys to account for minor post-validation design changes that do not trigger supplemental usability studies?
CLARIFIED ANSWER: FDA suggests that the approach seems logical but emphasizes that such specifics might require direct dialogue between the FDA and the company.
VERBATIM QUESTION: What is the FDA's stance on using real-time clinical usability surveys to account for minor post-validation design changes that do not trigger supplemental usability studies?
VERBATIM ANSWER: Yeah, I understand that a little bit better. And that does seem logical. Kris, do you have any additional comments at this time? We're kind of getting into very specifics here, so
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: real-time usability surveys, design changes, clinical validation
REVIEW FLAG: False

QA Block 16-10
CLARIFIED QUESTION: For devices with novel features or significant differences from existing products, what additional usability or validation considerations may be required?
CLARIFIED ANSWER: FDA recognizes both the traditional approach of conducting usability validation before clinical studies, and a flexibility-driven compressed approach that integrates usability and clinical testing to save time and cost. Developers should weigh the risks and decide accordingly.
VERBATIM QUESTION: For devices with novel features or significant differences from existing products, what additional usability or validation considerations may be required?
VERBATIM ANSWER: Yeah, so that's the traditional way of doing it, right  to do usability first, and then the clinical study second if everything looks good in the usability. Otherwise, you can make changes to your instructions or device that address any of the potential usability concerns. What the FDA has done for this is to provide flexibility to compress timelinesand shorten all of this down, and also potentially limit cost. But it does come with a risk, as I mentioned before. It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: usability validation, clinical study sequence, device development
REVIEW FLAG: False


#### 17. Switching Comparator Kits During Clinical Trials Guidelines

QA Block 17-2
CLARIFIED QUESTION: Is there anything specific that should be done when changing the comparator PCR kit during a clinical trial?
CLARIFIED ANSWER: Provide detailed information about the comparator change and patient count in an email to the FDA template box to ensure both comparators are acceptable. The FDA will review and provide specific feedback.
VERBATIM QUESTION: Is there anything specific that should be done when changing the comparator PCR kit during a clinical trial?
VERBATIM ANSWER: What I'd do is I would provide that information in the email to the templates. You started your study with-- and specified the comparator, and then you switched the study after X number of patients to the next comparator. And just make sure that we think both comparators are OK. I don't know that there's automatically a problem using-- making the switch, but we would want to give you very specific feedback on that.
SPEAKER QUESTION: Rakan Qazziha
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: changing comparator PCR kits, clinical trial requirements, specific feedback from FDA
REVIEW FLAG: False

QA Block 17-3
CLARIFIED QUESTION: Should the name of the comparator PCR kit be mentioned to ensure it is acceptable on the FDA's comparator PCR kits list?
CLARIFIED ANSWER: The FDA recommends emailing the templates box with details about starting with one comparator and switching to another, including comparator names, to confirm they are acceptable. Feedback will be provided.
VERBATIM QUESTION: Should the name of the comparator PCR kit be mentioned to ensure it is acceptable on the FDA's comparator PCR kits list?
VERBATIM ANSWER: Yeah, as far as names go, it's best if you send an email to our templates box and ask that. And then offline. So the other thing is I just want to clarify-- it sounded like you started your trial with one comparator, and then switched to another. What I'd do is I would provide that information in the email to the templates. You started your study with-- and specified the comparator, and then you switched the study after X number of patients to the next comparator. And just make sure that we think both comparators are OK. I don't know that there's automatically a problem using-- making the switch, but we would want to give you very specific feedback on that.
SPEAKER QUESTION: Rakan Qazziha
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: clinical trial comparator kits, PCR comparator acceptability, protocol changes
REVIEW FLAG: False


#### 18. Discrepancy Analysis Requirements for Molecular Diagnostic Tests

QA Block 18-1
CLARIFIED QUESTION: Regarding the discrepancy analysis for the clinical evaluation of a molecular diagnostic test for point of care use, does it only need to involve the samples that are discrepant between the candidate test and the first comparator test?
CLARIFIED ANSWER: The FDA advises that whether the discrepancy analysis must involve only discrepant samples or all samples depends on the study design and specific circumstances. They recommend discussing such questions in your submission or with your assigned reviewer.
VERBATIM QUESTION: Regarding the discrepancy analysis for the clinical evaluation of a molecular diagnostic test for point of care use, does it only need to involve the samples that are discrepant between the candidate test and the first comparator test?
VERBATIM ANSWER: It depends. And it also depends on your original study design. It also depends on what you want to do. That's a very specific question for your situation, so I would recommend that you ask that in your submission-- or if you've already submitted, that you ask your assigned reviewer about that.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: discrepancy analysis, molecular diagnostic testing, clinical evaluation
REVIEW FLAG: False


#### 19. Guidance on Asymptomatic Testing and EUA Applications

QA Block 19-1
CLARIFIED QUESTION: Should we continue the clinical study to supplement our EUA application for our antigen home test?
CLARIFIED ANSWER: FDA advises that this depends. If there is adequate performance in symptomatic cases (80% sensitivity and 70% lower confidence bound), the test may qualify for a serial testing claim with a post-market asymptomatic study commitment. Insufficient asymptomatic data pre-market won't support a single-test screening claim. Submit further details to the FDA inbox as needed.
VERBATIM QUESTION: Should we continue the clinical study to supplement our EUA application for our antigen home test?
VERBATIM ANSWER: So it depends. Just to give some high level-- and if you were one to have submitted a question beforehand, we are planning on responding by-- in detail by email. But just as a reminder, we still have the serial testing pathway for asymptomatic. So as long as there's adequate performance on symptomatics-- at least 80% sensitivity to high sensitivity molecular test and a lower 95% confidence lower bound of at least 70%-- you qualify for the serial testing claim for asymptomatics, with a post- market commitment to do an asymptomatic study. If you don't have sufficient numbers of asymptomatics pre-market, and are seeking a single test asymptomatic screening, then that's not going to be sufficient for that claim. So just at a high level, that's what I can respond to today. But again, if you have or-- already asked this question specifically of our inbox, we're planning on responding to that in the next day or two. Or if you haven't and you need the details, then you can submit an email to our templates email.
SPEAKER QUESTION: Sri Lekha Eedulakanti
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission, antigen home test, asymptomatic testing
REVIEW FLAG: False

QA Block 19-2
CLARIFIED QUESTION: What is the FDA's serial testing pathway for asymptomatic individuals and its associated performance criteria?
CLARIFIED ANSWER: The FDA allows a serial testing pathway for asymptomatic individuals if symptomatic results demonstrate at least 80% sensitivity to a high-sensitivity molecular test with a 95% confidence lower bound of at least 70%. This requires a post-market commitment to an asymptomatic study.
VERBATIM QUESTION: What is the FDA's serial testing pathway for asymptomatic individuals and its associated performance criteria?
VERBATIM ANSWER: Just to give some high level-- and if you were one to have submitted a question beforehand, we are planning on responding by-- in detail by email. But just as a reminder, we still have the serial testing pathway for asymptomatic. So as long as there's adequate performance on symptomatics-- at least 80% sensitivity to high sensitivity molecular test and a lower 95% confidence lower bound of at least 70%-- you qualify for the serial testing claim for asymptomatics, with a post- market commitment to do an asymptomatic study. If you don't have sufficient numbers of asymptomatics pre-market, and are seeking a single test asymptomatic screening, then that's not going to be sufficient for that claim.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serial testing, asymptomatic testing performance, FDA criteria
REVIEW FLAG: False

QA Block 19-3
CLARIFIED QUESTION: Can single test claims for asymptomatic screening be pursued if there are insufficient asymptomatic subjects enrolled in pre-market studies?
CLARIFIED ANSWER: Single test claims for asymptomatic screening cannot be pursued if there are insufficient pre-market asymptomatic subjects; however, serial testing claims are possible if symptomatic performance criteria are met, with a post-market asymptomatic study commitment.
VERBATIM QUESTION: Can single test claims for asymptomatic screening be pursued if there are insufficient asymptomatic subjects enrolled in pre-market studies?
VERBATIM ANSWER: So it depends. Just to give some high level-- and if you were one to have submitted a question beforehand, we are planning on responding by-- in detail by email. But just as a reminder, we still have the serial testing pathway for asymptomatic. So as long as there's adequate performance on symptomatics-- at least 80% sensitivity to high sensitivity molecular test and a lower 95% confidence lower bound of at least 70%-- you qualify for the serial testing claim for asymptomatics, with a post-market commitment to do an asymptomatic study. If you don't have sufficient numbers of asymptomatics pre-market, and are seeking a single test asymptomatic screening, then that's not going to be sufficient for that claim.
SPEAKER QUESTION: Sri Lekha Eedulakanti
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: asymptomatic screening, serial testing pathway, EUA requirements
REVIEW FLAG: False

QA Block 19-4
CLARIFIED QUESTION: What is the process for seeking clarification or additional information from the FDA regarding EUA applications for COVID-19 tests?
CLARIFIED ANSWER: To seek clarification or additional information regarding EUA applications for COVID-19 tests, email CDRH-EUA-Templates@fda.hhs.gov.
VERBATIM QUESTION: What is the process for seeking clarification or additional information from the FDA regarding EUA applications for COVID-19 tests?
VERBATIM ANSWER: For additional questions about today's town hall and COVID-19 IVD topics in general, please email CDRH-EUA-Templates@fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: EUA applications clarification, Contact FDA
REVIEW FLAG: False

QA Block 19-5
CLARIFIED QUESTION: Where can developers access recordings and transcripts of the FDA's Town Hall meetings on COVID-19 diagnostics?
CLARIFIED ANSWER: Recordings and transcripts of FDA's COVID-19 diagnostics Town Halls are available on CDRH Learn under Specialty Technical Topics and the Coronavirus COVID-19 Test Development and Validation Virtual Town Hall Series subsection.
VERBATIM QUESTION: Where can developers access recordings and transcripts of the FDA's Town Hall meetings on COVID-19 diagnostics?
VERBATIM ANSWER: As I mentioned earlier, a recording of today's Town Hall and a transcript will be made available on CDRH Learn. Please visit CDRH Learn at the link provided on this slide. You will find the recording and transcript under the section titled Specialty Technical Topics, and then the subsection titled Coronavirus COVID-19 Test Development and Validation Virtual Town Hall Series.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: Access to Town Hall materials, Town Hall recordings and transcripts
REVIEW FLAG: False

### removed qa blocks
QA Block 3-2
CLARIFIED QUESTION: Should a test developer notify the FDA of a different manufacturing site for an authorized test?
CLARIFIED ANSWER: FDA recommends that test developers notify them of any manufacturing site changes by emailing their lead reviewer and copying the email specific to their EUA number.
VERBATIM QUESTION: Should a test developer notify the FDA of a different manufacturing site for an authorized test?
VERBATIM ANSWER: Yes, we do recommend that test developers notify FDA of manufacturing site changes. And you can do this by sending an email to your lead reviewer, and copy the email address that is specific to your EUA number.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Manufacturing site changes, EUA process
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What are the requirements for obtaining a granted de novo classification for COVID-19 tests?
CLARIFIED ANSWER: The transcript section does not address the specific requirements for obtaining a granted de novo classification for COVID-19 tests.
VERBATIM QUESTION: What are the requirements for obtaining a granted de novo classification for COVID-19 tests?
VERBATIM ANSWER: NO RELEVANT ANSWER IN TRANSCRIPT
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: 
REVIEW FLAG: False
NOTES: Question not asked, granted de novo was discussed by FDA but not the specific requirements.

QA Block 6-3
CLARIFIED QUESTION: Are test developers required to monitor SARS-CoV-2 viral mutations for tests receiving full marketing authorization through de novo or 510k processes?
CLARIFIED ANSWER: FDA requires developers to monitor and evaluate the impact of SARS-CoV-2 viral mutations on test performance for as long as the test is offered. This applies to tests with EUA and those with full marketing authorization through de novo or 510k processes.
VERBATIM QUESTION: Are test developers required to monitor SARS-CoV-2 viral mutations for tests receiving full marketing authorization through de novo or 510k processes?
VERBATIM ANSWER: Yes. So we do expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations for as long as the test is being offered. This is included as a condition of authorization for all COVID-19 test EUAs. And we also expect this to be done for tests that receive full marketing authorization through a de novo or 510k. And we've included this in the special controls for the COVID-19 molecular test de novo that was granted last year.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: SARS-CoV-2 mutations, 510k and de novo processes, test performance requirements
REVIEW FLAG: False

QA Block 8-1
CLARIFIED QUESTION: Is the NIH ITAP program still active?
CLARIFIED ANSWER: The NIH ITAP program is still active, and developers can find program information and contact details through the provided slides. EUA authorizations are posted on the FDA's website following approval.
VERBATIM QUESTION: Is the NIH ITAP program still active?
VERBATIM ANSWER: Yes, the NIH ITAP program-- the Independent Test Assessment Program-- is still active. We have added the link for that program to the slide that is showing now. If developers are interested in the ITAP program, they can reach out directly through that link. And all EUA authorizations are posted to our website following authorization.
SPEAKER QUESTION: Commander Kimberly Piermatteo (FDA)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NIH ITAP program status, EUA authorizations
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: How can developers engage with the NIH ITAP program?
CLARIFIED ANSWER: Developers can engage with the NIH ITAP program by reaching out through the provided link.
VERBATIM QUESTION: How can developers engage with the NIH ITAP program?
VERBATIM ANSWER: If developers are interested in the ITAP program, they can reach out directly through that link.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: NIH ITAP program, developer engagement
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: How should operator-specific questions in a POC submission be addressed if POC clinical data is not submitted?
CLARIFIED ANSWER: FDA recommends explaining everything in your submission, linking the two submissions via the clinical study.
VERBATIM QUESTION: How should operator-specific questions in a POC submission be addressed if POC clinical data is not submitted?
VERBATIM ANSWER: Yeah, just explain everything in your submission. You can make two separate submissions, but do tell us that the two submissions are linked via the clinical study.
SPEAKER QUESTION: Sue Hart
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: POC submission, clinical data, submission requirements
REVIEW FLAG: False

QA Block 12-1
CLARIFIED QUESTION: What does the FDA consider the main challenges from a validation standpoint for a combined usability and clinical agreement study?
CLARIFIED ANSWER: The main challenge is discovering during the usability study that modifications are needed, such as workload instruction changes, which could invalidate the clinical study. Conducting the clinical portion first could mitigate bias, and while the approach saves time, it carries some risks.
VERBATIM QUESTION: What does the FDA consider the main challenges from a validation standpoint for a combined usability and clinical agreement study?
VERBATIM ANSWER: So the main risk, Jim, is that you find out in usability study that you have to modify something. Right? Workload instructions that are significant that would invalidate the clinical study. Thank you for appreciating the potential for bias and doing the clinical study first, and then the usability-- to show the usability of the test seems fine. I know of no issues why you can't take that risk if you're willing to, because it obviously does save time and resources to do that. But Kris and/or Toby may have some additional comments to make on this.
SPEAKER QUESTION: James Mullally
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation challenges, usability and clinical studies, study protocol risks
REVIEW FLAG: False

QA Block 12-8
CLARIFIED QUESTION: Does launching a test outside the U.S. lower the risk of challenges during combined usability and clinical agreement studies?
CLARIFIED ANSWER: Launching a test outside the U.S. and gaining prior experience with it can lower risks for combined usability and clinical agreement studies. Brand new tests entering the U.S. may benefit from mini studies to verify performance, though this is not required or always recommended.
VERBATIM QUESTION: Does launching a test outside the U.S. lower the risk of challenges during combined usability and clinical agreement studies?
VERBATIM ANSWER: First of all, if the test has been launched outside the U.S. and you have a lot of experience already with it, and it works fine, the risks may be lower. But if this is a brand new test-- you're coming first to the U.S., say-- and you don't have as much experience, then you may want to do some mini usability, mini clinical study to make sure that performance with those instructions is decent on a very small subset of users, even company personnel, just to verify that everything's-- that would mitigate some of the risk, obviously, if you did something that. But it's not required, not necessarily even recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Test launch outside U.S., Risk mitigation for studies, Mini usability and clinical studies
REVIEW FLAG: False

QA Block 12-10
CLARIFIED QUESTION: When is it appropriate to submit a study protocol under a Pre-EUA for FDA review?
CLARIFIED ANSWER: If you have specific questions about your study protocol, you may want to submit it as a Pre-EUA for FDA review.
VERBATIM QUESTION: When is it appropriate to submit a study protocol under a Pre-EUA for FDA review?
VERBATIM ANSWER: Yeah, I would just say that, if you have specific questions about the study protocol, you may want to submit that as a Pre-EUA. But otherwise, I think Tim covered our general thinking there.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pre-EUA submission, Study protocol questions
REVIEW FLAG: False

QA Block 16-5
CLARIFIED QUESTION: What factors should test developers consider when deciding between conducting usability validation before or during a clinical study?
CLARIFIED ANSWER: FDA recommends conducting usability validation before the clinical study to address usability concerns, reduce risks, and avoid stopping or restarting the study. Developers can opt for simultaneous usability and clinical testing to save time and costs, but this approach carries risks.
VERBATIM QUESTION: What factors should test developers consider when deciding between conducting usability validation before or during a clinical study?
VERBATIM ANSWER: To do usability first, and then the clinical study second if everything looks good in the usability. Otherwise, you can make changes to your instructions or device that address any of the potential usability concerns. What the FDA has done for this is to provide flexibility to compress timelines and shorten all of this down, and also potentially limit cost. But it does come with a risk, as I mentioned before. It could be unsafe in some way, and you have to stop the study. Or the usability test done at the same time, or essentially the same time, but after the clinical study testing and the session is done, that then you may spot something that needs to be changed, and you have to restart the clinical study too. We're just providing that flexibility. It's up to the developer to decide which path they want to take, the traditional or the shortened.
SPEAKER QUESTION: Heidi M.
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Usability validation, Clinical study sequencing, FDA flexibility
REVIEW FLAG: False

QA Block 17-1
CLARIFIED QUESTION: Is it allowed to change the comparator PCR kit during a clinical trial for an OTC antigen kit?
CLARIFIED ANSWER: FDA advises providing detailed information about the change in comparator PCR kits via email for review. Switching comparators may not automatically be an issue, but specific feedback will be provided.
VERBATIM QUESTION: Is it allowed to change the comparator PCR kit during a clinical trial for an OTC antigen kit?
VERBATIM ANSWER: What I'd do is I would provide that information in the email to the templates. You started your study with-- and specified the comparator, and then you switched the study after X number of patients to the next comparator. And just make sure that we think both comparators are OK. I don't know that there's automatically a problem using-- making the switch, but we would want to give you very specific feedback on that.
SPEAKER QUESTION: Rakan Qazziha
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Comparator PCR kit change, Clinical trials, FDA review process
REVIEW FLAG: False

QA Block 18-2
CLARIFIED QUESTION: For the discrepancy analysis in a molecular diagnostic test's clinical evaluation, must it involve all the samples included in the initial evaluation with the first comparator test?
CLARIFIED ANSWER: The requirement for discrepancy analysis involving all samples from the initial evaluation depends on the study design and specific goals. Users should consult their submission or assigned reviewer for guidance.
VERBATIM QUESTION: For the discrepancy analysis in a molecular diagnostic test's clinical evaluation, must it involve all the samples included in the initial evaluation with the first comparator test?
VERBATIM ANSWER: It depends. And it also depends on your original study design. It also depends on what you want to do. That's a very specific question for your situation, so I would recommend that you ask that in your submission-- or if you've already submitted, that you ask your assigned reviewer about that.
SPEAKER QUESTION: Ho-Jun Suk
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Discrepancy analysis, Molecular diagnostic tests, Study design
REVIEW FLAG: False

QA Block 19-6
CLARIFIED QUESTION: How can developers submit detailed questions about EUA applications or COVID-19 test development to the FDA?
CLARIFIED ANSWER: Developers can email detailed questions about EUA applications or COVID-19 test development to CDRH-EUA-Templates@fda.hhs.gov.
VERBATIM QUESTION: How can developers submit detailed questions about EUA applications or COVID-19 test development to the FDA?
VERBATIM ANSWER: For additional questions about today's town hall and COVID-19 IVD topics in general, please email CDRH- EUA-Templates@fda.hhs.gov.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Commander Kimberly Piermatteo (FDA)
TOPICS: EUA application questions, COVID-19 test development, FDA contact email
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-05 06:26:37 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 19
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the specific steps for developers to access and use Emory University and Children's Healthcare of Atlanta's Master File on pediatric self-swabbing?
QI 1-2: How should developers approach the FDA lead reviewers to leverage the pediatric swabbing study data?
QI 1-3: What details will be included in the website FAQs about pediatric self-swabbing?
QI 1-4: What additional precautions should manufacturers consider to prevent improper use of at-home COVID-19 tests?
QI 1-5: What guidance does the FDA provide on the proper storage of at-home COVID-19 tests to minimize risks to children and pets?
QI 1-6: How should developers address concerns about toxic chemicals in at-home tests when communicating with consumers?
QI 1-7: Are there any specific updates developers should be aware of regarding the expiration dates of at-home COVID-19 tests?

#### Section 2 of 19
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 2-1: What are the specific steps required to transition a COVID-19 test from an EUA to a full 510k authorization?
QI 2-2: Are there additional validation requirements for the first de novo submission compared to follow-on 510k submissions?
QI 2-3: What role do molecular comparators play in transitioning antigen tests to full authorization?
QI 2-4: When should developers begin considering the conversion from an EUA to a full authorization for their tests?
QI 2-5: What are the reasons for recommending developers to continue EUA studies into full authorization studies without interruption?
QI 2-6: How might a potential resurgence in COVID-19 cases impact the data collection process for EUA or full authorization submissions?
QI 2-7: What special controls are developed for the down-classification of antigen tests from de novo to 510k?

#### Section 3 of 19
##### Explicit Questions Extraction
QE 3-1: Should a test developer notify the FDA of an additional manufacturing site for an authorized test?
QE 3-2: Should a test developer notify the FDA of a different manufacturing site for an authorized test?

##### Implicit Questions Extraction
QI 3-1: How should a test developer handle questions that are too detailed or specific for the FDA Town Hall?
QI 3-2: How can a test developer follow up if they do not receive a response from the CDRH EUA templates email?
QI 3-3: What is the specific email address related to the EUA number that test developers should copy when notifying the FDA of manufacturing site changes?

#### Section 4 of 19
##### Explicit Questions Extraction
QE 4-1: Do laboratory-based qualitative serology tests require an EUA?

##### Implicit Questions Extraction
QI 4-1: What are the requirements for obtaining a granted de novo classification for COVID-19 tests?
QI 4-2: What does the FDA mean by 'traditional marketing authorization' in the context of COVID-19 tests?
QI 4-3: Where can developers find the November 15, 2021 update to the COVID-19 test policy guidance?
QI 4-4: Are there any updates in the November 15, 2021 COVID-19 test policy guidance that affect the EUA process for LDTs?

#### Section 5 of 19
##### Explicit Questions Extraction
QE 5-1: Are reagent stability studies required to be conducted with panels of samples derived from natural clinical matrix to support a 510(k)?

##### Implicit Questions Extraction
QI 5-1: What analyte concentration range should be used for spiking negative clinical matrices in reagent stability studies?
QI 5-2: Are recombinant proteins acceptable for reagent stability studies?

#### Section 6 of 19
##### Explicit Questions Extraction
QE 6-1: Will FDA accept supplements to existing EUAs after the FDA stops accepting new EUA requests?
QE 6-2: For authorized tests, will the FDA expect developers to continue routinely monitoring and evaluating the performance impact of SARS-CoV-2 viral mutations?

##### Implicit Questions Extraction
QI 6-1: Are test developers required to monitor SARS-CoV-2 viral mutations for tests receiving full marketing authorization through de novo or 510k processes?
QI 6-2: What are the conditions of authorization that must be maintained for COVID-19 test EUAs?
QI 6-3: What steps should developers take if they require further clarity on the transition guidance for emergency use devices?
QI 6-4: How should developers provide sufficient details when contacting the EUA templates mailbox for feedback on their plans?
QI 6-5: Is the FDA currently accepting 510k submissions for molecular COVID-19 tests?
QI 6-6: What is the FDA's plan for granting full marketing authorization for COVID-19 antigen or serology tests?
QI 6-7: What is the process for submitting a comment to the docket if there are unclear aspects in the transition plan guidance?

#### Section 7 of 19
##### Explicit Questions Extraction
QE 7-1: Do test developers need to evaluate the stealth omicron variant?
QE 7-2: What is currently considered a significant frequency for mutations observed in sequence databases?
QE 7-3: Should developers consult the viral mutations guidance for additional details?
QE 7-4: What steps should be taken if developers have specific questions about their test or evaluation of specific variants?

##### Implicit Questions Extraction
QI 7-1: What steps should developers follow to evaluate the impact of the BA.2 variant?
QI 7-2: How should developers use the GISAID database to assess the prevalence of mutations?
QI 7-3: What does the FDA consider a significant frequency for mutations in sequence databases in relation to BA.2?
QI 7-4: What time frame is recommended for evaluating mutation prevalence in sequence databases?
QI 7-5: Where can developers find further details about mutation evaluation methods?

#### Section 8 of 19
##### Explicit Questions Extraction
QE 8-1: Is the NIH ITAP program still active?
QE 8-2: Have there been any recent EUA authorizations through the NIH ITAP program?

##### Implicit Questions Extraction
QI 8-1: Where can developers find the link to the NIH ITAP program?
QI 8-2: How can developers engage with the NIH ITAP program?
QI 8-3: Where are EUA authorizations posted after approval?

#### Section 9 of 19
##### Explicit Questions Extraction

##### Implicit Questions Extraction

#### Section 10 of 19
##### Explicit Questions Extraction
QE 10-1: Is there a necessity that results reporting will be required when companies convert to a full 510k authorization?
QE 10-2: If results reporting is required under a full 510k authorization, will companies need to provide a mobile phone app or website to users?

##### Implicit Questions Extraction
QI 10-1: Does the FDA require connectivity for point-of-care and at-home tests as part of full authorization?
QI 10-2: What are the FDA's expectations for incorporating voluntary reporting mechanisms for home tests?
QI 10-3: Are there specific requirements for lab-based reporting that differ from home-based test reporting?
QI 10-4: Do the special controls for molecular 510k devices require test result reporting or connectivity features?

#### Section 11 of 19
##### Explicit Questions Extraction
QE 11-1: Could we use a completed clinical study from a home test submission for a point of care EUA submission?
QE 11-2: Could we include the OTC study in a POC submission while also submitting an OTC request?
QE 11-3: How should operator-specific questions in a POC submission be addressed if POC clinical data is not submitted?
QE 11-4: Can a rejected EUA submission be resubmitted as a brand new request after fixing issues?

##### Implicit Questions Extraction
QI 11-1: Does an OTC study automatically fulfill the requirements for a point of care (POC) EUA test if approved?
QI 11-2: What criteria need to be met for an OTC submission to also qualify for a professional version EUA?
QI 11-3: If a kit is used for both OTC and POC, what specific variable factors should be addressed in testing?
QI 11-4: What information should be included in the cover letters when submitting linked OTC and POC submissions?
QI 11-5: How should a developer justify not submitting POC clinical study data while addressing operator-specific questions in the same submission?
QI 11-6: Is it necessary to include guard band testing results in EUA submissions for tests used in both OTC and POC settings?
QI 11-7: How should feedback from a prior declined EUA submission be incorporated into a resubmission?

#### Section 12 of 19
##### Explicit Questions Extraction
QE 12-1: What does the FDA consider the main challenges from a validation standpoint for a combined usability and clinical agreement study?
QE 12-2: Can potential training bias in a combined usability and clinical agreement study be mitigated by having the subject conduct the clinical agreement study portion of the test first and then the usability study?
QE 12-3: Does the FDA foresee other challenges in a combined usability and clinical agreement study, such as identification of significant issues that could render the clinical study null and void?
QE 12-4: Should labeling changes be required in the case of significant issues during a combined usability and clinical agreement study, and how does this impact the study?

##### Implicit Questions Extraction
QI 12-1: What risks does the FDA associate with making modifications to workload instructions after beginning a clinical study?
QI 12-2: Can conducting a mini usability or mini clinical study mitigate risks for developers of new diagnostic tests entering the U.S. market?
QI 12-3: Is it advisable to test on a small subset of users, like company personnel, before embarking on a large-scale study, even though it is not required?
QI 12-4: Does launching a test outside the U.S. lower the risk of challenges during combined usability and clinical agreement studies?
QI 12-5: Are there alternative approaches to mitigate risks in a combined usability and clinical agreement study if the test is new to the U.S. and lacks extensive prior use?
QI 12-6: When is it appropriate to submit a study protocol under a Pre-EUA for FDA review?

#### Section 13 of 19
##### Explicit Questions Extraction
QE 13-1: If we resubmit using data from a previous submission, can we use 10 positive sequences for sequencing, or do we need to provide more than 10, such as 30 plus additional positives?
QE 13-2: Can we use our previous pre-omicron data for the resubmission?
QE 13-3: Can we contact our previously assigned lead reviewer to ask specific questions about the submission if the project was closed?

##### Implicit Questions Extraction
QI 13-1: How should developers ensure that their comparator assays meet FDA requirements?
QI 13-2: What are the FDA's specific requirements for sequencing omicron samples in new studies?
QI 13-3: If sequencing for omicron samples cannot be completed on all samples in a timely manner, how should developers prioritize which samples to sequence?
QI 13-4: Should sequencing data for omicron-positive samples be submitted pre- or post-authorization?
QI 13-5: Are there alternative strategies for meeting FDA sequencing requirements for omicron samples during times when omicron is predominant?
QI 13-6: Is it acceptable to submit an EUA without complete sequencing data for omicron, and address the sequencing requirements in post-submission dialogue?
QI 13-7: What kind of post-market performance data for omicron samples might the FDA expect?

#### Section 14 of 19
##### Explicit Questions Extraction
QE 14-1: Would a home use molecular test be able to use BioFire as a predicate, or would it require a de novo?

##### Implicit Questions Extraction

#### Section 15 of 19
##### Explicit Questions Extraction
QE 15-1: Is there any indication presently that the public health emergency (PHE), last signed on January 14 and good for 90 days, is going to be extended or renewed?

##### Implicit Questions Extraction
QI 15-1: What is the difference between the Secretary of HHS's declaration for EUAs and the public health emergency declaration?
QI 15-2: Does the Secretary of HHS's declaration for EUAs have an expiration date or other time constraints?
QI 15-3: What past examples exist of similar declarations (e.g., Zika, Ebola) remaining active beyond the public health emergency?
QI 15-4: What is the status of the transition guidance related to EUAs and how can developers provide feedback?

#### Section 16 of 19
##### Explicit Questions Extraction
QE 16-1: Should usability validation be conducted prior to the clinical study to ensure safe and effective use before starting the clinical study?
QE 16-2: Would incorporating a usability survey with pointed questions during the clinical study help demonstrate that the usability and comprehension of the device reflect the same success as the usability validation?
QE 16-3: Is it acceptable, in FDA's opinion, to show that the usability perception of the user and the performance in the clinical study reflect the same results from the usability study, especially if there are minor changes that don't require supplemental usability studies?
QE 16-4: Can data from usability surveys conducted during clinical studies be used as supplemental data to support a statement of safe and effective use?

##### Implicit Questions Extraction
QI 16-1: What factors should test developers consider when deciding between conducting usability validation before or during a clinical study?
QI 16-2: What are potential risks for usability testing and clinical studies if conducted simultaneously rather than sequentially?
QI 16-3: Does the FDA recommend timeline compression for usability validation and clinical studies if it reduces costs despite associated risks?
QI 16-4: In cases where usability testing identifies issues after clinical studies begin, how should developers address these problems without restarting the entire study?
QI 16-5: What is the FDA's stance on using real-time clinical usability surveys to account for minor post-validation design changes that do not trigger supplemental usability studies?
QI 16-6: For devices with novel features or significant differences from existing products, what additional usability or validation considerations may be required?

#### Section 17 of 19
##### Explicit Questions Extraction
QE 17-1: Is it allowed to change the comparator PCR kit during a clinical trial for an OTC antigen kit?
QE 17-2: Is there anything specific that should be done when changing the comparator PCR kit during a clinical trial?
QE 17-3: Should the name of the comparator PCR kit be mentioned to ensure it is acceptable on the FDA's comparator PCR kits list?

##### Implicit Questions Extraction

#### Section 18 of 19
##### Explicit Questions Extraction
QE 18-1: Regarding the discrepancy analysis for the clinical evaluation of a molecular diagnostic test for point of care use, does it only need to involve the samples that are discrepant between the candidate test and the first comparator test?
QE 18-2: For the discrepancy analysis in a molecular diagnostic test's clinical evaluation, must it involve all the samples included in the initial evaluation with the first comparator test?

##### Implicit Questions Extraction

#### Section 19 of 19
##### Explicit Questions Extraction
QE 19-1: Should we continue the clinical study to supplement our EUA application for our antigen home test?

##### Implicit Questions Extraction
QI 19-1: What is the FDA's serial testing pathway for asymptomatic individuals and its associated performance criteria?
QI 19-2: Can single test claims for asymptomatic screening be pursued if there are insufficient asymptomatic subjects enrolled in pre-market studies?
QI 19-3: What is the process for seeking clarification or additional information from the FDA regarding EUA applications for COVID-19 tests?
QI 19-4: Where can developers access recordings and transcripts of the FDA's Town Hall meetings on COVID-19 diagnostics?
QI 19-5: How can developers submit detailed questions about EUA applications or COVID-19 test development to the FDA?
